EBIX INC Form 10-Q August 10, 2015 Table of Contents

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q

QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE

b ACT OF 1934

For the quarterly period ended June 30, 2015

OR

TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES

EXCHANGE ACT OF 1934

Commission file number 0-15946

Ebix, Inc.

(Exact name of registrant as specified in its charter)

DELAWARE 77-0021975

(State or other jurisdiction of incorporation or (I.R.S. Employer Identification No.)

organization)

1 EBIX WAY

JOHNS CREEK, GEORGIA 30097 (Address of principal executive offices) (Zip Code)

Registrant's telephone number, including area code: 678-281-2020

Former address of registrant: 5 Concourse Parkway; Suite 3200, Atlanta, GA 30328

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes \flat No o Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files). Yes \flat No o

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, or a non-accelerated filer.

Non-accelerated filer o

Large accelerated filer o

Accelerated filer b

(Do not check if a smaller

reporting company)

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes o No b

As of August 7, 2015 the number of shares of common stock outstanding was 34,456,930.

FORM 10-Q

FOR THE QUARTER ENDED JUNE 30, 2015

INDEX

PART I — FINANCIAL INFORMATION

<u>Item 1. Consolidated Financial Statements</u>

| Condensed Consolidated Statements of Income for the three and six months ended June 30, 2015 and 2014 (unaudited) | 2 |
|---|-----------|
| Condensed Consolidated Statements of Comprehensive Income for the three and six months ended June 30, 2015 and 2014 (unaudited) | <u>3</u> |
| Condensed Consolidated Balance Sheets at June 30, 2015 (unaudited) and December 31, 2014 | <u>4</u> |
| Condensed Consolidated Statement of Stockholders' Equity for the six months ended June 30, 2015 (unaudited) | <u>6</u> |
| Condensed Consolidated Statements of Cash Flows for the six months ended June 30, 2015 and 2014 (unaudited) | 7 |
| Notes to Condensed Consolidated Financial Statements (unaudited) | 9 |
| Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations | <u>24</u> |
| Item 3. Quantitative and Qualitative Disclosures About Market Risk | <u>36</u> |
| Item 4. Controls and Procedures | <u>37</u> |
| PART II — OTHER INFORMATION | |
| Item 1. Legal Proceedings | <u>37</u> |
| Item 1A. Risk Factors | <u>38</u> |
| Item 2. Repurchases of Equity Securities | <u>39</u> |
| Item 3. Defaults upon Senior Securities | <u>39</u> |
| Item 4. Mine Safety Disclosures | <u>39</u> |
| Item 5. Other Information | <u>39</u> |
| Item 6. Exhibits | <u>39</u> |
| <u>SIGNATURES</u> | <u>40</u> |
| EXHIBIT INDEX | <u>41</u> |
| | |

Exhibit 31.1

Exhibit 31.2 Exhibit 32.1

Exhibit 32.2

Exhibit 101

PART I — FINANCIAL INFORMATION

Item 1: CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

Ebix, Inc. and Subsidiaries Condensed Consolidated Statements of Income (In thousands, except per share data) (Unaudited)

| | Three Month June 30, | s Ended | Six Months Ended June 30 | | |
|--|----------------------|----------|-----------------------------|-----------|--|
| | 2015 | 2014 | 2015 | 2014 | |
| Operating revenue | \$64,712 | \$51,476 | \$128,465 | \$102,880 | |
| Operating expenses: | | | | | |
| Cost of services provided | 18,699 | 9,964 | 38,184 | 19,576 | |
| Product development | 7,288 | 6,758 | 14,335 | 13,451 | |
| Sales and marketing | 3,611 | 3,784 | 6,990 | 7,085 | |
| General and administrative, net (see Note 3) | 12,121 | 11,068 | 22,867 | 20,909 | |
| Amortization and depreciation | 2,570 | 2,441 | 5,167 | 4,993 | |
| Total operating expenses | 44,289 | 34,015 | 87,543 | 66,014 | |
| Operating income | 20,423 | 17,461 | 40,922 | 36,866 | |
| Interest income | 44 | 130 | 105 | 265 | |
| Interest expense | (625) | (211) | (1,344) | (458) | |
| Non-operating (loss)/income - put options | | (139) | | 315 | |
| Foreign currency exchange gain (loss) | 330 | (336) | 1,222 | (455) | |
| Income before income taxes | 20,172 | 16,905 | 40,905 | 36,533 | |
| Income tax expense | • | • | • | (7,537) | |
| Net income | \$19,036 | \$13,579 | \$37,372 | \$28,996 | |
| Basic earnings per common share | \$0.54 | \$0.35 | \$1.06 | \$0.76 | |
| Diluted earnings per common share | \$0.54 | \$0.35 | \$1.05 | \$0.75 | |
| Basic weighted average shares outstanding | 35,046 | 38,427 | 35,375 | 38,373 | |
| Diluted weighted average shares outstanding | 35,269 | 38,647 | 35,610 | 38,624 | |

See accompanying notes to the condensed consolidated financial statements.

Table of Contents

Ebix, Inc. and Subsidiaries Condensed Consolidated Statements of Comprehensive Income (In thousands) (Unaudited)

| | Three Months Ended June 30, | | Six Months Ended June 30, | |
|--|-----------------------------|----------|---------------------------|--|
| | 2015 | 2014 | 2015 2014 | |
| Net income | \$19,036 | \$13,579 | \$37,372 \$28,996 | |
| Other comprehensive income (loss): | | | | |
| Foreign currency translation adjustments | 1,366 | 1,471 | \$(4,034) 2,599 | |
| Total other comprehensive income (loss) | 1,366 | 1,471 | (4,034) 2,599 | |
| Comprehensive income | \$20,402 | \$15,050 | \$33,338 \$31,595 | |

See accompanying notes to the condensed consolidated financial statements.

Table of Contents

Ebix, Inc. and Subsidiaries

| Condensed Consolidated Balance Sheets | | |
|---|------------------|-------------------|
| (In thousands, except share amounts) | | |
| | June 30, 2015 | December 31, 2014 |
| ASSETS | (Unaudited) | |
| Current assets: | | |
| Cash and cash equivalents | \$27,423 | \$52,300 |
| Short-term investments | 974 | 281 |
| Trade accounts receivable, less allowances of \$1,449 and \$1,619, respectively | 47,217 | 41,100 |
| Deferred tax asset, net | 2,115 | 2,113 |
| Other current assets | 9,933 | 8,067 |
| Total current assets | 87,662 | 103,861 |
| Property and equipment, net | 32,250 | 24,661 |
| Goodwill | 412,842 | 402,220 |
| Intangibles, net | 51,656 | 49,371 |
| Indefinite-lived intangibles | 30,887 | 30,887 |
| Deferred tax asset, net | 23,191 | 18,758 |
| Other assets | 5,766 | 4,553 |
| Total assets | \$644,254 | \$634,311 |
| LIABILITIES AND STOCKHOLDERS' EQUITY | | |
| Current liabilities: | | |
| Accounts payable and accrued liabilities | \$23,099 | \$40,121 |
| Accrued payroll and related benefits | 6,229 | 5,280 |
| Current portion of long term debt and capital lease obligations, net of discount of \$9 and \$7, respectively | 617 | 936 |
| Current deferred rent | 289 | 268 |
| Contingent liability for accrued earn-out acquisition consideration | 1,887 | 887 |
| Deferred revenue | 20,612 | 22,192 |
| Other current liabilities | 102 | 102 |
| Total current liabilities | 52,835 | 69,786 |
| Total Carrent MacMilles | 22,022 | 05,700 |
| Revolving line of credit | 150,465 | 120,465 |
| Long term debt and capital lease obligations, less current portion, net of discount of \$0 and \$7, respectively | 43 | 593 |
| Other liabilities | 2,447 | 2,179 |
| Contingent liability for accrued earn-out acquisition consideration | 8,193 | 4,480 |
| Deferred revenue | 1,803 | 2,496 |
| Long term deferred rent | 1,901 | 2,091 |
| Total liabilities | 217,687 | 202,090 |
| Commitments and Contingencies, Note 5 | | |
| Stockholders' equity: | | |
| Preferred stock, \$0.10 par value, 500,000 shares authorized, no shares issued and outstanding at June 30, 2015 and December 31, 2014 | _ | _ |
| outstanding at June 30, 2013 and December 31, 2014 | 3,494 | 3,619 |
| | 5,777 | 3,017 |

Common stock, \$0.10 par value, 60,000,000 shares authorized, 34,937,055 issued and outstanding, at June 30,2015 and 36,232,074 issued and 36,191,565 outstanding at December 31,2014

Additional paid-in capital 103,547 137,101

Table of Contents

| Treasury stock (no shares as of June 30, 2015 and 40,509 shares as of December 31, 2014) | _ | (76 |) |
|--|-----------|-----------|---|
| , | 244 500 | 200 726 | |
| Retained earnings | 341,709 | 309,726 | |
| Accumulated other comprehensive loss | (22,183 |) (18,149 |) |
| Total stockholders' equity | 426,567 | 432,221 | |
| Total liabilities and stockholders' equity | \$644,254 | \$634,311 | |
| See accompanying notes to the condensed consolidated financial statements. | | | |
| | | | |
| 5 | | | |

Table of Contents

Ebix, Inc. and Subsidiaries Condensed Consolidated Statements of Stockholders' Equity (unaudited) (In thousands except for share figures)

Common Stock

| | Common Ste | OK. | | | | | | |
|---------------------------------------|------------------|---------|-------------|-------------|-----------------------------------|---|--|-------------|
| | Issued Shares | Amount | • | Stock | yAdditional Paid-in Capital | Retained Earnings | Accumulated Other Comprehensiv Loss | Total ve |
| Balance, December 31, 2014 | 36,232,074 | \$3,619 | (40,509) | \$ (76) | \$137,101 | \$309,726 | \$ (18,149) | \$432,221 |
| Net income | | | _ | _ | _ | 37,372 | | 37,372 |
| Cumulative translation | | | | | | 01,012 | (4.024 | |
| adjustment | _ | | | | | _ | (4,034) | (4,034) |
| Repurchase and | | | | | | | | |
| retirement of common | (1,344,234) | (135) | | | (34,346) | | | (34,481) |
| stock | | | | | | | | |
| Vesting of restricted | 71,514 | 8 | _ | | (8) | | | _ |
| stock | | | | | | | | 1 115 |
| Exercise of stock options Share based | \$ 56,250 | 6 | _ | _ | 1,111 | _ | | 1,117 |
| compensation | _ | _ | | _ | 839 | _ | | 839 |
| Tax benefit related to | | | | | | | | |
| share-based | _ | _ | _ | _ | 63 | _ | | 63 |
| compensation | | | | | | | | |
| Forfeiture of certain | | | | | | | | |
| shares to satisfy exercise | | | | | | | | |
| costs and the recipients | | | | | | | | |
| income tax obligations | (38,040) | (4) | | _ | (1,137) | _ | | (1,141) |
| related to stock options | | | | | | | | |
| exercised and restricted | | | | | | | | |
| stock vested | | | | | | | | |
| Retirement of treasury stock | (40,509) | _ | 40,509 | 76 | (76) | _ | | |
| Dividends paid | _ | _ | | | | (5,389) | | (5,389) |
| Balance, June 30, 2015 | 34,937,055 | \$3,494 | | \$ — | \$103,547 | \$341,709 | \$ (22,183) | \$426,567 |
| See accompanying notes | | | lidated fir | ' | | , - , - , - , - , - , - , - , - , - , - | , , | , |

Table of Contents

Ebix, Inc. and Subsidiaries Condensed Consolidated Statements of Cash Flows (In thousands) (Unaudited)

| (Unaudited) | G: 3.6 | | |
|--|----------|-----------|---|
| | Six Mont | hs Ended | |
| | June 30, | | |
| | 2015 | 2014 | |
| Cash flows from operating activities: | | *** | |
| Net income | \$37,372 | \$28,996 | |
| Adjustments to reconcile net income to net cash provided by operating activities: | | | |
| Depreciation and amortization | 5,167 | 4,993 | |
| Benefit for deferred taxes | (6,014 |) (1,668 |) |
| Share based compensation | 839 | 882 | |
| Provision for doubtful accounts | 301 | 748 | |
| Debt discount amortization on promissory note payable | 8 | 18 | |
| Unrealized foreign exchange (gain) loss | (920 |) 517 | |
| Loss on put option | | (315 |) |
| Reduction of acquisition earnout accruals | | (1,762 |) |
| Changes in assets and liabilities, net of effects from acquisitions: | | , | |
| Accounts receivable | (3,662 |) (2,992 |) |
| Other assets | (2,606 |) 917 | |
| Accounts payable and accrued expenses | (18,802 |) (1,914 |) |
| Accrued payroll and related benefits | 1,104 | 2,007 | , |
| Deferred revenue | (2,036 |) (1,128 |) |
| Deferred rent | (125 |) (195 |) |
| Reserve for potential uncertain income tax return positions | 108 | 3,866 | , |
| Liability - securities litigation settlement payment | (690 |) (4,218 |) |
| Other liabilities | 111 | (128 |) |
| Net cash provided by operating activities | 10,155 | 28,624 | , |
| Net cash provided by operating activities | 10,133 | 20,024 | |
| Cash flows from investing activities: | | | |
| Acquisition of Media Health, net of cash acquired | (1,000 |) — | |
| Acquisition of P.B. Systems, net of cash acquired | | , | |
| | (11,480 |) — | |
| Acquisition of HealthCare Magic, net of cash acquired | _ | (5,856 |) |
| Acquisition of CurePet, Inc., net of cash acquired | | 3 | |
| Payment of acquisition earn-out contingency, Taimma | | (2,250 |) |
| Purchases of marketable securities | (704 |) (567 |) |
| Capital expenditures | (10,312 |) (13,852 |) |
| Net cash used in investing activities | (23,496 |) (22,522 |) |
| č | , | , , , | |
| Cash flows from financing activities: | | | |
| Proceeds from / (Repayments) on revolving line of credit, net | 30,000 | (15,000 |) |
| Principal payments of term loan obligation | | (4,813 |) |
| Repurchases of common stock | (34,481 |) (2,234 |) |
| Excess tax benefit from share-based compensation | 63 | (3,200 |) |
| Proceeds from the exercise of stock options | 1,117 | 788 | , |
| Forfeiture of certain shares to satisfy exercise costs and the recipients income tax | | | |
| obligations related to stock options exercised and restricted stock vested | (1,141 |) (30 |) |
| G | | | |

| (5,389) | (5,793 |) |
|----------|--|---|
| (623) | (321 |) |
| (1) | (103 |) |
| (10,455) | (30,706 |) |
| (1,081) | 833 | |
| (24,877) | (23,771 |) |
| 52,300 | 56,674 | |
| \$27,423 | \$32,903 | |
| | | |
| \$2,964 | \$436 | |
| \$20,926 | \$6,774 | |
| | (623) (1) (10,455) (1,081) (24,877) 52,300 \$27,423 | (623) (321 (1) (103 (10,455) (30,706 (1,081) 833 (24,877) (23,771 52,300 56,674 \$27,423 \$32,903 \$2,964 \$436 |

See accompanying notes to the condensed consolidated financial statements.

Supplemental schedule of noncash financing activities:

Effective January 27, 2014 Ebix acquired the entire business of CurePet, Inc. ("CurePet") in an asset purchase agreement with the total purchase consideration being in the amount of \$6.35 million of which included a possible future one time contingent earnout payment of up to \$5.0 million based on earned revenues over the subsequent thirty-six month period following the date of the acquisition. This contingent earnout liability is estimated to have a fair value of zero. Additional required cash consideration

Table of Contents

of \$1.35 million was offset against open receivable balances due to Ebix, Inc. from CurePet, and therefore no actual cash outlay was made by Ebix, Inc. Previously during 2012, Ebix acquired a minority 19.8% interest in CurePet for cash consideration in the amount of \$2.0 million.

During the six months ended June 30, 2015 there were 38,040 shares, totaling \$1.14 million, used to satisfy exercise costs and the recipients income tax obligations related to stock options exercised and restricted stock vesting.

Table of Contents

Ebix, Inc. and Subsidiaries

Notes to Condensed Consolidated Financial Statements

Note 1: Description of Business and Summary of Significant Accounting Policies

Description of Business— Ebix, Inc. and subsidiaries ("Ebix" or the "Company") is an international supplier of on-demand software and e-commerce solutions to the insurance industry. Ebix provides various application software products for the insurance industry ranging from data exchanges, carrier systems, and agency systems, to custom software development for business entities across the insurance industry. The Company's products feature fully customizable and scalable on-demand software applications designed to streamline the way insurance professionals manage distribution, marketing, sales, customer service, and accounting activities. The Company has its headquarters in Atlanta, Georgia and also conducts operating activities in Australia, Canada, India, New Zealand, Singapore, United Kingdom and Brazil. International revenue accounted for 23.7% and 32.7% of the Company's total revenue for the six months ended June 30, 2015 and 2014, respectively.

The Company's revenues are derived from four product/service groups. Presented in the table below is the breakout of our revenue streams for each of those product/service groups for the three and six months ended June 30, 2015 and 2014.

| | Three Months Ended | | Six Months Ended | |
|-----------------------------------|--------------------|----------|------------------|-----------|
| | June 30, | | June 30, | |
| (dollar amounts in thousands) | 2015 | 2014 | 2015 | 2014 |
| Exchanges | \$46,825 | \$41,350 | \$93,503 | \$83,455 |
| Broker Systems | 3,519 | 4,865 | 7,255 | 9,351 |
| Risk Compliance Solutions ("RCS") | 13,289 | 3,652 | 25,464 | 7,077 |
| Carrier Systems | 1,079 | 1,609 | 2,243 | 2,997 |
| Totals | \$64,712 | \$51,476 | \$128,465 | \$102,880 |

Summary of Significant Accounting Policies

Basis of Presentation—The accompanying unaudited condensed consolidated financial statements and these notes have been prepared pursuant to the rules and regulations of the Securities and Exchange Commission ("SEC") and in accordance with U.S. Generally Accepted Accounting Principles ("GAAP") with the effect of inter-company balances and transactions eliminated. Certain information and note disclosures normally included in annual financial statements prepared in accordance with GAAP and SEC rules have been condensed or omitted as permitted by and pursuant to those rules and regulations, although the Company believes that the disclosures made are adequate to make the information not misleading. These unaudited condensed consolidated financial statements contain adjustments (consisting only of normal recurring items) necessary to fairly present the consolidated financial position of the Company and its consolidated results of operations and cash flows. Operating results for the six months ended June 30, 2015 and 2014 are not necessarily indicative of the results that may be expected for future quarters or the full year of 2015. The condensed consolidated December 31, 2014 balance sheet included in this interim period filing has been derived from the audited financial statements at that date but does not necessarily include all of the information and related notes required by GAAP for complete financial statements. These condensed interim financial statements should be read in conjunction with the financial statements and notes thereto included in the Company's Annual Report on Form 10-K for the year ended December 31, 2014.

Reclassification—The change in reserve for potential uncertain income tax return positions had been previously netted against the provision for deferred taxes line in the consolidated statements of cash flows, it is now shown separately. Also, beginning in 2014 the Company has applied the new provisions under Financial Accounting Standard ("FAS") update No. 2013-11, Presentation of an Unrecognized Tax Benefit When a Net Operating Loss Carryforward, A Similar Tax Loss, or a Tax Credit Carryforward Exists and as more fully described in Note 6 "Income Taxes". A portion of potential uncertain income tax return positions previously reported in "Other Liabilities" on the condensed

consolidated balance sheets are now netted against the "Deferred tax asset, net" line in the long term asset section of the condensed consolidated balance sheets.

Advertising—With the exception of certain direct-response costs, advertising costs are expensed as incurred. Advertising costs amounted to \$1.3 million and \$416 thousand in the first six months of 2015 and 2014, respectively, and are included in sales and marketing expenses in the accompanying Condensed Consolidated Statements of Income. Sales and marketing expenses have been reduced in the first six months of 2015 as a result of the deferment of (net of amortization) \$2.2 million of certain direct-

Table of Contents

response advertising costs associated with our recent acquisition of Oakstone, which have been capitalized in accordance with Accounting Standards Codification ("ASC") Topic 340. These costs are being amortized to expense over periods ranging from twelve to twenty-four months based on the type of product the customer purchases. Fair Value of Financial Instrument—The Company follows the relevant GAAP guidance concerning fair value measurements which provides a consistent framework to define, measure, and disclose the fair value of assets and liabilities in financial statements. Fair value is defined as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction. This guidance establishes a three-level hierarchy priority for disclosure of assets and liabilities recorded at fair value. The ordering of priority reflects the degree to which objective data from external active markets are available to measure fair value. The classification of assets and liabilities within the hierarchy is based on whether the inputs to the valuation methodology used for measurement are observable or unobservable.

Level 1 Inputs - Unadjusted quoted prices available in active markets for identical investments to the reporting entity at the measurement date

Level 2 Inputs - Other than quoted prices included in Level 1 inputs that are observable for the asset or liability, either directly or indirectly, for substantially the full term of the asset or liability.

Level 3 Inputs - Unobservable inputs, which are used to the extent that observable inputs are not available, and used in situations where there is little or no market activity for the asset or liability and wherein the reporting entity makes estimates and assumptions related to the pricing of the asset or liability including assumptions regarding risk.

A financial instrument's level within the fair value hierarchy is based on the lowest level of any input that is significant to the fair value measurement.

As of June 30, 2015 the Company had the following financial instruments to which it had to consider fair values and had to make fair assessments:

Short-term investments for which the fair values are measured as a Level 1 instrument.

Contingent accrued earn-out business acquisition consideration liabilities for which fair values are measured as Level 3 instruments. These contingent consideration liabilities were recorded at fair value on the acquisition date and are remeasured quarterly based on the then assessed fair value and adjusted if necessary. The increases or decreases in the fair value of contingent consideration payable can result from changes in anticipated revenue levels and changes in assumed discount periods and rates. As the fair value measure is based on significant inputs that are not observable in the market, they are categorized as Level 3.

Other financial instruments not measured at fair value on the Company's unaudited condensed consolidated balance sheet at June 30, 2015 but which require disclosure of their fair values include: cash and cash equivalents, accounts receivable, accounts payable and accrued expenses, accrued payroll and related benefits, capital lease obligations, and debt under the revolving line of credit with Regions Financial Corporation. The Company believes that the estimated fair value of such instruments at June 30, 2015 and December 31, 2014, approximates their carrying value as reported on the unaudited Condensed Consolidated Balance Sheet.

Additional information regarding the Company's assets and liabilities that are measured at fair value on a recurring basis is presented in the following tables:

| | Fair Values at Reporting Date Using* | | | | | | |
|---|---------------------------------------|---|---|--------------|--|--|--|
| Descriptions | Balance, June 30 2015 (In thousands) | Quoted Prices in Active Markets I, for Identical Assets or Liabilities (Level 1) | Significant Other Observable Inputs (Level 2) | Unobservable | | | |
| Assets | (In thousands) | | | | | | |
| Available-for-sale securities: | | | | | | | |
| Commercial bank certificates of deposits | \$974 | \$974 | \$ — | \$ — | | | |
| Total assets measured at fair value | \$974 | \$974 | \$ — | \$ — | | | |
| Liabilities | | | | | | | |
| Derivatives: | | | | | | | |
| Contingent accrued earn-out acquisition consideration (a) | 10,080 | _ | _ | 10,080 | | | |
| Total liabilities measured at fair value | \$10,080 | \$ — | \$— | \$10,080 | | | |

⁽a) The income valuation approach is applied and the valuation inputs include the contingent payment arrangement terms, projected cash flows, rate of return, and probability assessments.

^{*} During the three months ended June 30, 2015 there were no transfers between fair value Levels 1, 2 or 3.

| | Fair Values at Reporting Date Using* | | | | | |
|---|--------------------------------------|--|---|---|--|--|
| | | Quoted Prices in | | | | |
| Descriptions | Balance, December 31, 2014 | Active Markets for Identical Assets or Liabilities (Level 1) | Significant Other Observable Inputs (Level 2) | Significant Unobservable Inputs (Level 3) | | |
| | (In thousands) | | | | | |
| Assets | | | | | | |
| Available-for-sale securities: | | | | | | |
| Commercial bank certificates of deposits | \$281 | 281 | \$ — | \$ — | | |
| Total assets measured at fair value | \$281 | \$281 | \$ — | \$ — | | |
| Liabilities Derivatives: | | | | | | |
| Contingent accrued earn-out acquisition consideration (a) | 5,367 | _ | _ | 5,367 | | |
| Total liabilities measured at fair value | \$5,367 | \$ — | \$ — | \$5,367 | | |

⁽a) The income valuation approach is applied and the valuation inputs include the contingent payment arrangement terms, projected cash flows, rate of return, and probability assessments.

^{*} During the twelve months ended December 31, 2014 there were no transfers between fair value Levels 1, 2 or 3.

Table of Contents

12

For the Company's assets and liabilities measured at fair value on a recurring basis using significant unobservable inputs (Level 3), the following table provides a reconciliation of the beginning and ending balances for each category therein, and gains or losses recognized during the six months ended June 30, 2015 and during the year ended December 31, 2014:

Fair Value Measurements Using Significant Unobservable Inputs (Level 3)

| Contingent Liability for Accrued Earn-out Acquisition Consideration | Balance, June 30, 2015 (in thousands) | Balance, December 31, 2014 | |
|---|---------------------------------------|----------------------------|---|
| Beginning balance | \$5,367 | \$ 14,420 | |
| Total remeasurement adjustments: (Gains) or losses included in earnings ** Foreign currency translation adjustments *** | - 13 | (10,237 (314 |) |
| Acquisitions and settlements Business acquisitions Settlement payments | 4,700 — | 4,312 (2,814 |) |
| Ending balance | \$10,080 | \$5,367 | |
| The amount of total (gains) or losses for the period included in earnings or changes to net assets, attributable to changes in unrealized (gains) or losses relating to assets or liabilities still held at period-end. | \$ | \$(8,911 |) |

^{**} recorded as an adjustment to reported general and administrative expenses

Quantitative Information about Level 3 Fair Value Measurements

The significant unobservable inputs used in the fair value measurement of the Company's contingent consideration liabilities designated as Level 3 are as follows:

| (in thousands) | Fair Value at June 30, 2015 | Valuation Technique | Significant Unobservable Input |
|--|-----------------------------|----------------------|--|
| Contingent acquisition consideration: (Qatarlyst, HealthCare Magic, Vertex, i3, and PB Systems acquisitions) | \$10,080 | Discounted cash flow | Projected revenue and probability of achievement |

^{***} recorded as a component of other comprehensive income within stockholders' equity

Table of Contents

Significant Fair Value at December Valuation Technique Unobservable (in thousands)

31, 2014

Input

Projected revenue and Contingent acquisition consideration:

(Qatarlyst, HealthCare Magic, \$5,367 Discounted cash flow probability of Vertex, and i3 acquisitions) achievement

Sensitivity to Changes in Significant Unobservable Inputs

As presented in the table above, the significant unobservable inputs used in the fair value measurement of contingent consideration related to business acquisitions are projected revenue forecasts as developed by the relevant members of Company's management team and the probability of achievement of those revenue forecasts. The discount rate used in these calculations is 1.75%. Significant increases (decreases) in these unobservable inputs in isolation would result in a significantly higher (lower) fair value measurement.

Revenue Recognition—The Company derives its revenues primarily from subscription and transaction fees pertaining to services delivered over our exchanges or from our ASP platforms, fees for risk compliance solution services, and fees for software development projects including associated fees for consulting, implementation, training, and project management provided to customers with installed systems and applications. Sales and value-added taxes are not included in revenues, but rather are recorded as a liability until the taxes assessed are remitted to the respective taxing

In accordance with Financial Accounting Standard Board ("FASB") and SEC accounting guidance on revenue recognition, the Company considers revenue earned and realizable when: (a) persuasive evidence of the sales arrangement exists, provided that the arrangement fee is fixed or determinable, (b) delivery or performance has occurred, (c) customer acceptance has been received or is assured, if contractually required, and (d) collectability of the arrangement fee is probable. The Company uses signed contractual agreements as persuasive evidence of a sales arrangement. We apply the provisions of the relevant generally accepted accounting principles related to all transactions involving the license of software where the software deliverables are considered more than inconsequential to the other elements in the arrangement.

For contracts that contain multiple deliverables, we analyze the revenue arrangements in accordance with the relevant technical accounting guidance, which provides criteria governing how to determine whether goods or services that are delivered separately in a bundled sales arrangement should be considered as separate units of accounting for the purpose of revenue recognition. These types of arrangements include deliverables pertaining to software licenses, system set-up, and professional services associated with product customization or modification. Delivery of the various contractual elements typically occurs over periods of less than eighteen months. These arrangements generally do not have refund provisions or have very limited refund terms.

Software development arrangements involving significant customization, modification or production are accounted for in accordance with the appropriate technical accounting guidance issued by FASB using the percentage-of-completion method. The Company recognizes revenue using periodic reported actual hours worked as a percentage of total expected hours required to complete the project arrangement and applies the percentage to the total arrangement fee.

Accounts Receivable and the Allowance for Doubtful Accounts Receivable—Reported accounts receivable include \$37.1 million of trade receivables stated at invoice billed amounts net of the estimated allowance for doubtful accounts receivable in the amount of \$1.4 million, and \$10.1 million of unbilled receivables. The unbilled receivables pertain to certain projects for which the timing of billing is tied to contractual milestones. The Company adheres to such contractually stated performance milestones and accordingly issues invoices to customers as per contract billing schedules, Approximately \$5.5 million of deferred revenue is included in billed accounts receivable at June 30, 2015. The Company recognized and recorded bad debt expense in the amount of \$292 thousand and \$301 thousand for the three and six-month periods ended June 30, 2015 and \$395 thousand and \$748 thousand for the three and six-month periods ended June 30, 2014, respectively. Accounts receivable are written off against the allowance account when the Company has exhausted all reasonable collection efforts. During the six months ending June 30, 2015 \$470 thousand

of accounts receivable were written off.

Goodwill and Other Indefinite-Lived Intangible Assets—Goodwill represents the cost in excess of the fair value of the net assets of acquired businesses. Indefinite-lived intangible assets represent the fair value of certain acquired contractual customer relationships for which future cash flows are expected to continue indefinitely. In accordance with the relevant FASB accounting guidance, goodwill and indefinite-lived intangible assets are not amortized but are tested for impairment at the reporting unit level on an annual basis or on an interim basis if an event occurs or circumstances change that would likely have reduced the fair value

of a reporting unit below its carrying value. Potential impairment indicators include a significant change in the business climate, legal factors, operating performance indicators, competition, and the sale or disposition of a significant portion of the business. The impairment evaluation process involves an assessment of certain qualitative factors to determine whether the existence of events or circumstances would indicate that it is more likely than not that the fair value of any of our reporting units was less than its carrying amount. If after assessing the totality of events or circumstances, we were to determine that it is not more likely than not that the fair value of a reporting unit is less than its carrying amount, then the Company would not perform the two-step quantitative impairment testing described further below.

The aforementioned two-step quantitative testing process involves comparing the reporting unit carrying values to their respective fair values; we determine fair value of our reporting units by applying the discounted cash flow method using the present value of future estimated net cash flows. If the fair value of a reporting unit exceeds its carrying value, then no further testing is required. However, if a reporting unit's fair value were to be less than its carrying value, we would then determine the amount of the impairment charge, if any, which would be the amount that the carrying value of the reporting unit's goodwill exceeded its implied value. Projections of cash flows are based on our views of growth rates, operating costs, anticipated future economic conditions and the appropriate discount rates relative to risk and estimates of residual values. We believe that our estimates are consistent with assumptions that marketplace participants would use in their estimates of fair value. The use of different estimates or assumptions for our projected discounted cash flows (e.g., growth rates, future economic conditions, discount rates and estimates of terminal values) when determining the fair value of our reporting units could result in different values and may result in a goodwill impairment charge. We perform our annual goodwill impairment evaluation and testing as of September 30th of each year. This evaluation is done during the fourth quarter each year. During the year ended December 31, 2014 we had no impairment of our reporting unit goodwill balances.

Changes in the carrying amount of goodwill for the six months ended June 30, 2015 and the year ended December 31, 2014 are reflected in the following table.

| | June 30, 2015 | December 31, 2014 | |
|--|----------------|-------------------|--|
| | (In thousands) | | |
| Beginning Balance | \$402,220 | \$337,068 | |
| Additions | 12,025 | 68,503 | |
| Foreign currency translation adjustments | (1,403 |) (3,351) | |
| Ending Balance | \$412,842 | \$402,220 | |

Finite-lived Intangible Assets—Purchased intangible assets represent the estimated acquisition date fair value of customer relationships, developed technology, trademarks and non-compete agreements obtained in connection with the businesses we acquire. We amortize these intangible assets on a straight-line basis over their estimated useful lives, as follows:

| Category | Life (yrs) |
|------------------------|------------|
| Customer relationships | 7-20 |
| Developed technology | 3–12 |
| Trademarks | 3–15 |
| Non-compete agreements | 5 |
| Database | 10 |

The carrying value of finite-lived and indefinite-lived intangible assets at June 30, 2015 and December 31, 2014 are as follows:

| | June 30, | December 3 | 1, |
|------------------------------------|---------------|------------|----|
| | 2015 | 2014 | |
| | (In thousands |) | |
| Finite-lived intangible assets: | | | |
| Customer relationships | \$70,572 | \$66,783 | |
| Developed technology | 17,638 | 15,664 | |
| Trademarks | 2,756 | 2,751 | |
| Non-compete agreements | 751 | 751 | |
| Backlog | 140 | 140 | |
| Database | 212 | 212 | |
| Total intangibles | 92,069 | 86,301 | |
| Accumulated amortization | (40,413 |) (36,930 |) |
| Finite-lived intangibles, net | \$51,656 | \$49,371 | |
| Indefinite-lived intangibles: | | | |
| Customer/territorial relationships | \$30.887 | \$30.887 | |

Amortization expense recognized in connection with acquired intangible assets was \$1.8 million and \$3.6 million for the three and six months ended June 30, 2015 and \$1.8 million and \$3.7 million for the three and six months ended June 30, 2014, respectively.

Foreign Currency Translation—The functional currency for the Company's foreign subsidiaries in India and Singapore is the U.S. dollar because the intellectual property research and development activities is provided by its Singapore subsidiary, and the product development and information technology enabled services activities for the insurance industry is provided by its India subsidiary, both in support of Ebix's operating divisions across the world, are transacted in U.S. dollars.

The functional currency of the Company's other foreign subsidiaries is the local currency of the country in which the subsidiary operates. The assets and liabilities of these foreign subsidiaries are translated into U.S. dollars at the rates of exchange at the balance sheet dates. Income and expense accounts are translated at the average exchange rates in effect during the period. Gains and losses resulting from translation adjustments are included as a component of accumulated other comprehensive income in the accompanying consolidated balance sheets, and are included in the condensed consolidated statements of comprehensive income. Foreign exchange transaction gains and losses that are derived from transactions denominated in a currency other than the subsidiary's functional currency are included in the determination of net income.

Income Taxes—Deferred income taxes are recorded to reflect the estimated future tax effects of differences between the financial statement and tax basis of assets, liabilities, operating losses, and tax credit carry forwards using the tax rates expected to be in effect when the temporary differences reverse. Valuation allowances, if any, are recorded to reduce deferred tax assets to the amount management considers more likely than not to be realized. Such valuation allowances are recorded for the portion of the deferred tax assets that are not expected to be realized based on the levels of historical taxable income and projections for future taxable income over the periods in which the temporary differences will be deductible.

The Company also applies FASB accounting guidance on accounting for uncertainty in income taxes positions. This guidance clarifies the accounting for uncertainty in income taxes by prescribing the minimum recognition threshold a tax position is required to meet before being recognized in the financial statements. In this regard we recognize the tax benefit from uncertain tax positions only if it is more likely than not that the tax position will be sustained on examination by the taxing authorities, based on the technical merits of the position.

Recent Relevant Accounting Pronouncements—The following is a brief discussion of recently released accounting pronouncements that are pertinent to the Company's business:

In November 2014 the FASB issued Accounting Standards Update ("ASU") No. 2014-17 "Business Combinations Pushdown Accounting (a consensus of the FASB Emerging Issues Task Force). The amendments in this ASU apply to the separate financial statements of an acquired entity and its subsidiaries that are a business (either public or nonpublic) upon the occurrence

Table of Contents

of an event in which an acquirer (an individual or an entity) obtains control of the acquired entity. The amendments in this ASU provide an acquired entity with an option to apply pushdown accounting in its separate financial statements upon occurrence of an event in which an acquirer obtains control of the acquired entity. An acquired entity may elect the option to apply pushdown accounting in the reporting period in which the change-in-control event occurs. If pushdown accounting is not applied in the reporting period in which the change-in-control event occurs, an acquired entity will have the option to elect to apply pushdown accounting in a subsequent reporting period to the acquired entity's most recent change-in-control event. An election to apply pushdown accounting in a reporting period after the reporting period in which the change-in-control event occurred should be considered a change in accounting principle. If pushdown accounting is applied to an individual change-in-control event, that election is irrevocable. If an acquired entity elects the option to apply pushdown accounting in its separate financial statements, it should disclose information in the current reporting period that enables users of financial statements to evaluate the effect of pushdown accounting. The amendments in this ASU were effective on November 18, 2014. After the effective date, an acquired entity can make an election to apply the guidance to future change-in-control events or to its most recent change-in-control event. The Company has adopted this ASU.

In May 2014 the FASB issued ASU No. 2014-09, "Revenue from Contracts with Customers". ASU 2014-09 affects any entity using U.S. GAAP that either enters into contracts with customers to transfer goods or services or enters into contracts for the transfer of nonfinancial assets unless those contracts are within the scope of other standards (e.g., insurance contracts or lease contracts). This ASU will supersede the revenue recognition requirements in Topic 605, Revenue Recognition, and most industry-specific guidance. This ASU also supersedes some cost guidance included in Subtopic 605-35, Revenue Recognition—Construction-Type and Production-Type Contracts. In addition, the existing requirements for the recognition of a gain or loss on the transfer of nonfinancial assets that are not in a contract with a customer (e.g., assets within the scope of Topic 360, Property, Plant, and Equipment, and intangible assets within the scope of Topic 350, Intangibles—Goodwill and Other) are amended to be consistent with the guidance on recognition and measurement (including the constraint on revenue) in this ASU.

The core principle of the guidance is that an entity should recognize revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. To achieve that core principle, an entity should apply the following steps:

- Step 1: Identify the contract(s) with a customer.
- Step 2: Identify the performance obligations in the contract.
- Step 3: Determine the transaction price.
- Step 4: Allocate the transaction price to the performance obligations in the contract.
- Step 5: Recognize revenue when (or as) the entity satisfies a performance obligation.

For a public entity, the amendments in this ASU are effective for annual reporting periods beginning after December 15, 2016, including interim periods within that reporting period. Early application is not permitted.

An entity should apply the amendments in this ASU using one of the following two methods:

1. Retrospectively to each prior reporting period presented and the entity may elect any of the following practical expedients:

For completed contracts, an entity need not restate contracts that begin and end within the same annual reporting period.

For completed contracts that have variable consideration, an entity may use the transaction price at the date the contract was completed rather than estimating variable consideration amounts in the comparative reporting periods. For all reporting periods presented before the date of initial application, an entity need not disclose the amount of the transaction price allocated to remaining performance obligations and an explanation of when the entity expects to recognize that amount as revenue.

2. Retrospectively with the cumulative effect of initially applying this ASU recognized at the date of initial application. If an entity elects this transition method it also should provide the additional disclosures in reporting periods that include the date of initial application of:

The amount by which each financial statement line item is affected in the current reporting period by the application of this ASU as compared to the guidance that was in effect before the change.

An explanation of the reasons for significant changes.

Although early adoption is allowed, the Company plans to adopt this new accounting standard on its newly revised effective date of January 1, 2018, but it has not presently determined the impact that the adoption of ASU No. 2014-09 will have

on its income statement, balance sheet, or statement of cash flows. Furthermore, the Company has not yet determined the method of retrospective adoption it will use as described in first and second paragraphs immediately above.

Note 2: Earnings per Share

A reconciliation between basic and diluted earnings per share is as follows (in thousands, except per share data):

| | Three Months Ended | | Six Months Ended | |
|--|---------------------------------------|----------|------------------|----------|
| | June 30, | | June 30, | |
| | 2015 | 2014 | 2015 | 2014 |
| | (In thousands, except per share data) | | | |
| Net income for basic and diluted earnings per share | \$19,036 | \$13,579 | \$37,372 | \$28,996 |
| Basic Weighted Average Shares Outstanding | 35,046 | 38,427 | 35,375 | 38,373 |
| Dilutive effect of stock options and restricted stock awards | 223 | 220 | 235 | 251 |
| Diluted weighted average shares outstanding | 35,269 | 38,647 | 35,610 | 38,624 |
| Basic earnings per common share | \$0.54 | \$0.35 | \$1.06 | \$0.76 |
| Diluted earnings per common share | \$0.54 | \$0.35 | \$1.05 | \$0.75 |

Note 3: Business Combinations

The Company seeks to execute accretive business acquisitions in combination with organic growth initiatives as part of its comprehensive business growth and expansion strategy, which primarily consist of businesses that are complementary to Ebix's existing products and services.

During the six months ended June 30, 2015, the Company completed two business acquisitions.

The Company acquired PB Systems, Inc. and PB Systems Private Limited (together being "PB Systems"), effective June 1, 2015. PB Systems develops and implements software solutions for insurance clients. Ebix acquired PB Systems for upfront cash consideration in the amount of \$12.4 million, plus possible future contingent earnout payments of up to \$8.0 million based on earned revenues over the subsequent twenty-four month period following the effective date of the acquisition. The valuation and purchase price allocation for the PB Systems acquisition is preliminary and will be finalized prior to December 31, 2015.

The Company acquired Via Media Health Communications Private Limited ("Via Media Health"), effective March 1, 2015. Via Media Health is one of India's leading health content and communication companies. Ebix acquired Via Media Health for upfront cash consideration in the amount of \$1.0 million, plus a possible future one time contingent earnout payment of up to \$372 thousand based on earned revenues over the subsequent twelve month period following the effective date of the acquisition, and an additional possible one time future performance bonus depending upon revenue growth realized in the business over the subsequent twenty-four month period following the effective date of the acquisition. The valuation and purchase price allocation for the Via Media Health acquisition remains preliminary and will be finalized prior to September 30, 2015.

Effective December 2, 2014, Ebix acquired Oakstone Publishing, LLC ("Oakstone") in a membership interest purchase agreement for total net cash consideration in the amount of \$23.72 million (\$31.37 million less a closing net working capital adjustment of \$7.65 million). Oakstone is leading provider of continuing education, certification materials for physicians, dentists and allied healthcare professionals, as well as wellness resources for various organizations. Ebix acquired all of the outstanding membership interests of Oakstone and funded the purchase using a mix of internal cash reserves and the bank credit line available to Ebix. The Company accounted for this acquisition by recording \$28.8 million of goodwill, \$1.7 million of intangible assets pertaining to customer relationships, \$501 thousand of intangible assets pertaining to acquired technology, and a \$6.5 million

deferred revenue liability. The valuation and purchase price allocation for the Oakstone acquisition remains preliminary and will be finalized prior to September 30, 2015.

On December 1, 2014, Ebix acquired the DCM Group Inc. (d.b.a. i3 Software) ("i3") in an asset purchase agreement for total cash consideration in the amount of \$2 million and a possible contingent earnout of up to \$4 million based on earned revenues over the subsequent twenty-four month period following the date of the acquisition. i3 is a provider of software services and solutions to the insurance industry. Ebix acquired all of the assets of i3 and funded the purchase using internal cash reserves. The Company accounted for this acquisition by recording \$3.7 million of goodwill, \$225 thousand of intangible assets pertaining to customer relationships, and \$75 thousand of intangible assets pertaining to acquired technology. The valuation and purchase price allocation for the i3 acquisition remains preliminary and will be finalized prior to September 30, 2015.

On November 3, 2014, Ebix acquired Vertex, Incorporated ("Vertex"), with an effective date of October 1, 2014, in a share purchase agreement for total cash purchase consideration in the amount of \$27.25 million and a possible contingent earnout of \$2 million based on earned revenues over the subsequent twenty-four month period following the date of the acquisition. Vertex is a specialized software and services firm focused primarily on the life and annuity insurance marketplace since 1991. Ebix acquired all of the outstanding capital stock of Vertex and funded the purchase using a mix of internal cash reserves and the bank credit line available to Ebix. The Company accounted for this acquisition by recording \$27.7 million of goodwill, \$2.5 million of intangible assets pertaining to customer relationships, and \$235 thousand of intangible assets pertaining to acquired technology. The valuation and purchase price allocation for the Vertex acquisition remains preliminary and will be finalized prior to September 30, 2015.

On May 21, 2014, Ebix acquired HealthCare Magic Private Limited ("HealthCare Magic"), a medical advisory service with an online network of approximately fifteen thousand General Physicians and Surgeons spread across fifty specialties including alternative medicine. The Company acquired HealthCare Magic for aggregate cash consideration in the amount of \$6.0 million plus a possible future one time contingent earnout payment of up to \$12.36 million based on earned revenues over the subsequent twenty-four month period following the effective date of the acquisition. This contingent earnout liability is currently estimated to have a fair value of \$596 thousand. The Company funded the HealthCare Magic acquisition from available cash reserves on hand. The Company accounted for this acquisition by recording \$5.6 million of goodwill, \$452 thousand of intangible assets pertaining to customer relationships, \$100 thousand of intangible assets pertaining to acquired technology, \$59 thousand on intangible assets pertaining to trademarks and tradenames, and \$226 thousand of intangible assets pertaining to non-compete agreements.

On January 27, 2014, Ebix acquired CurePet. CurePet was a developmental-stage enterprise that developed an insurance exchange that connects pet owners, referring veterinarians, animal hospitals, academic institutes, and suppliers of medical and general pet supplies, while providing a wide variety of services related to pet insurance to each constituent including practice management, electronic medical records, and billing. Previously Ebix had a minority investment in CurePet. Ebix acquired the entire business of CurePet in an asset purchase agreement with total purchase consideration being \$6.35 million which includes a possible future one time contingent earnout payment of up to \$5.0 million based on earned revenues over the subsequent thirty-six month period following the effective date of the acquisition. This contingent earnout liability is currently estimated to have a fair value of zero. Additional required cash consideration of \$1.35 million was offset against open accounts receivable balances due to the Company from CurePet, and no actual cash outlay was made by the Company.

A significant component of the purchase price consideration for many of the Company's business acquisitions is a potential subsequent cash earnout payment based on reaching certain specified future revenue targets. The Company recognizes these potential obligations as contingent liabilities and are reported accordingly on its Condensed Consolidated Balance Sheets. As discussed in more detail in Note 1, these contingent consideration liabilities are recorded at fair value on the acquisition date and are remeasured quarterly based on the then assessed fair value and adjusted if necessary. During the three months ended June 30, 2015 and 2014 these aggregate contingent accrued earn-out business acquisition consideration liabilities were reduced by zero and \$1.8 million, respectively, due to

remeasurements as based on the then assessed fair value and changes in anticipated future revenue levels. These reductions to the contingent accrued earn-out liabilities resulted in a corresponding reduction to general and administrative expenses as reported on the Condensed Consolidated Statements of Income. As of June 30, 2015, the total of these contingent liabilities was \$10.08 million, of which \$8.19 million is reported in long-term liabilities, and \$1.89 million is included in current liabilities in the Company's Condensed Consolidated Balance Sheet. As of December 31, 2014 the total of these contingent liabilities was \$5.37 million, of which \$4.48 million is reported in long-term liabilities, and \$887 thousand is included in current liabilities in the Company's Condensed Consolidated Balance Sheet.

Consideration paid by the Company for the businesses it purchases is allocated to the assets and liabilities acquired based upon their estimated fair values as of the date of the acquisition. The excess of the purchase price over the estimated fair values

of assets acquired and liabilities assumed is recorded as goodwill. Recognized goodwill pertains to the value of the expected synergies to be derived from combining the operations of the businesses we acquire including the value of the acquired workforce.

The aggregated unaudited pro forma financial information pertaining to all of the Company's acquisitions made during the six months ended June 30, 2014 and June 30, 2015, which includes the acquisitions of CurePet (acquired in January 2014), Via Media Health (acquired in March 2015), and PB Systems (acquired June 2015), as well as the effect of other businesses acquired in 2014, namely HealthCare Magic (May 2014), Vertex (October 2014), Oakstone (December 2014), and i3 (December 2014), as presented in the table below is provided for informational purposes only and does not project the Company's expected results of operations for any future period. No effect has been given in this pro forma information for future synergistic benefits that may still be realized as a result of combining these companies or costs that may yet be incurred in integrating their operations. The 2015 and 2014 pro forma financial information below assumes that all such business acquisitions were made on January 1, 2014, whereas the Company's reported financial statements for the three and six months ended June 30, 2015 only include the operating results from these businesses since the effective date that they were acquired by Ebix.

| | Three Months Ended | | Three Months Ended | | Six Months Ending | | Six Months Ending | |
|-------------|--------------------|--------------------------------------|--------------------|-----------|--------------------|-----------|-------------------|-----------|
| | June 30, 2015 | | June 30, 2014 | | June 30, 2015 | | June 30, 2014 | |
| | As | Pro Forma | As | Pro Forma | As | Pro Forma | As | Pro Forma |
| | Reported | Pro Forma | Reported Pro Forma | Reported | leported Pro Forma | Reported | rio romia | |
| | (unaudited) | audited) (unau | |) | (unaudited) | | (unaudited) | |
| | (In thousan | In thousands, except per share data) | | | | | | |
| Revenue | \$64,712 | \$68,813 | \$51,476 | \$70,351 | \$128,465 | \$135,218 | \$102,880 | \$139,519 |
| Net Income | \$19,036 | \$19,616 | \$13,579 | \$13,796 | \$37,372 | \$37,602 | \$28,996 | \$28,910 |
| Basic EPS | \$0.54 | \$0.56 | \$0.35 | \$0.36 | \$1.06 | \$1.06 | \$0.76 | \$0.75 |
| Diluted EPS | \$0.54 | \$0.56 | \$0.35 | \$0.36 | \$1.05 | \$1.06 | \$0.75 | \$0.75 |

In the above table, the unaudited pro forma revenue for the three months ended June 30, 2015 decreased by \$1.5 million from the unaudited pro forma revenue during the same period in 2014 of \$70.4 million to \$68.8 million, representing a 2.2% decrease. Correspondingly, the reported revenue for the three months ended June 30, 2015 increased by \$13.2 million or 25.7% from the reported revenue during the same period in 2014. The unaudited pro forma revenue for the six months ended June 30, 2015 decreased by \$4.3 million from the unaudited pro forma revenue during the same period in 2014 of \$139.5 million to \$135.2 million, representing a 3.1% decrease. Correspondingly, the reported revenue for the six months ended June 30, 2015 increased by \$25.6 million or 24.9% from the reported revenue during the same period in 2014.

Note 4: Debt with Commercial Bank

On February 3, 2015, Ebix, Inc. and certain of its subsidiaries entered into the First Amendment (the "First Amendment") to the Regions Secured Credit Facility, dated August 5, 2014, among the Company, Regions Financial Corporation as Administrative Agent ("Regions"), with Regions, MUFG Union Bank N.A., and Silicon Valley Bank as joint lenders. The First Amendment amends the Regions Credit Facility by increasing the maximum amount by which the Aggregate Revolving Commitments may be increased to \$90 million from the pre-existing limit of \$50 million, increases the amount of base facility to \$190 million from the pre-existing amount of \$150 million, which together with the \$50 million accordion feature increases the total Credit Agreement capacity amount to \$240 million from the prior amount of \$200 million, and expands the syndicated bank group to four participants by adding Fifth Third Bank.

On August 5, 2014, Ebix entered into a credit agreement providing for a \$150 million secured syndicated credit facility (the "Regions Secured Credit Facility") with Regions as administrative agent and Regions with MUFG Union

Bank N.A., and Silicon Valley Bank as joint lenders. The financing is comprised of a five-year, \$150 million secured revolving credit facility, with an option to expand to \$200 million upon request and with additional lender commitments. This new \$150 million credit facility with Regions, as administrative agent, replaced the former syndicated \$100 million facility that the Company had in place with Citi Bank, N.A. which was paid in full upon the undertaking of this new loan facility with Regions. The interest rate applicable to the Secured Syndicated Credit Facility is LIBOR plus 1.50%. Under the Regions Secured Credit Facility the maximum interest rate that could be charged depending upon the Company's leverage ratio is LIBOR plus 2.25%. The underlying financing agreement contains financial covenants regarding the Company's fixed charge coverage ratio and leverage ratio, as well as certain restrictive covenants pertaining to such matters as the incurrence of new debt and the consummation of new business acquisitions. The

Company currently is in compliance with all such financial and restrictive covenants. As of June 30, 2015 the Company's consolidated balance sheet includes \$1.40 million of remaining deferred financing costs.

At June 30, 2015, the outstanding balance on the revolving line of credit under the Regions Secured Credit Facility was \$150.5 million and the facility carried an interest rate of 1.94%. During the six months ended June 30, 2015, no payments were made against the revolving line of credit. The revolving line of credit balance is included in the long-term liabilities section of the Condensed Consolidated Balance Sheets. During the six months period ended June 30, 2015, the average and maximum outstanding balances on our revolving line of credit facilities were \$133.5 million and \$150.5 million, respectively.

Note 5: Commitments and Contingencies

Contingencies-On December 3, 2012, the Company received a subpoena and letter from the SEC dated November 30, 2012, stating that the SEC is conducting a formal, non-public investigation styled In the Matter of Ebix, Inc. (A-3318) and seeking documents primarily related to the issues raised in the In re: Ebix, Inc. Securities Litigation. On April 16, 2013, the Company received a second subpoena from the SEC seeking additional documents. The Company has cooperated with the SEC to provide the requested documents.

On June 6, 2013, the Company was notified that the U.S. Attorney for the Northern District of Georgia had opened an investigation into allegations of intentional misconduct that had been brought to its attention from the pending shareholder class action lawsuit against the Company's directors and officers, the media and other sources. The Company has cooperated with the U.S. Attorney's office.

Following the announcement on May 1, 2013 of the Company's execution of a merger agreement with affiliates of Goldman Sachs & Co., twelve putative class action complaints challenging the proposed merger were filed in the Delaware Court of Chancery. These complaints name as Defendants some combination of the Company, its directors, Goldman Sachs & Co. and affiliated entities. On June 10, 2013, the twelve complaints were consolidated by the Delaware Court of Chancery, now captioned In re Ebix, Inc. Stockholder Litigation, CA No. 8526-VCN. On June 19, 2013, the Company announced that the merger agreement had been terminated pursuant to a Termination and Settlement Agreement. After Defendants moved to dismiss the consolidated proceeding, Lead Plaintiffs amended their operative complaint to drop their claims against Goldman Sachs & Co. and focus their allegations on an Acquisition Bonus Agreement ("ABA") between the Company and Robin Raina. On September 26, 2013, Defendants moved to dismiss the Amended Consolidated Complaint. On July 24, 2014, the Court issued its Memorandum Opinion. The only surviving counts are as follows: (i) Counts II and IV, but only to the extent the Plaintiffs seek non-monetary relief for alleged material misstatements related to the ABA base price in the 2010 Proxy Statement; (ii) Count II, but only to the extent it challenges the continued existence of the ABA as an alleged unreasonable anti-takeover device; and, (iii) Count V, but only to the extent that it relates to the compensation the Board received under the Company's 2010 Stock Incentive Plan. On September 15, 2014, the Court entered an Order implementing its Memorandum Opinion. On January 16, 2015, the Court entered an Order permitting Plaintiffs to file a Second Amended and Supplemented Complaint naming the individual directors and the Company as Defendants. As currently pled, the Second Amended and Supplemented Complaint asserts (i) a purported class and derivative claim for breach of fiduciary duty by the individual Defendants in improperly maintaining the ABA as an unreasonable anti-takeover device; (ii) a purported class claim against the individual Defendants for breach of the fiduciary duty of disclosure to the stockholders with respect to the Company's 2010 Proxy Statement and 2010 Stock Incentive Plan, (iii) a purported derivative claim against the individual Defendants for breach of fiduciary duty to the Company in causing incentive compensation to be awarded to themselves and others under the 2010 Stock Incentive Plan, (iv) a purported class and derivative claim for breach of fiduciary duty by the individual Defendants in adopting the August 5, 2014 Credit Agreement, the November 26, 2014 Director Nomination Agreement with Barrington Capital Group, L.P. and certain bylaw amendments adopted December 19, 2014, (v) a purported class and derivative claim seeking invalidation of the December 19, 2014 bylaw amendments under Delaware law, and (vi) a purported class claim for breach of fiduciary

duty by the individual Defendants for issuing a purportedly materially misleading and incomplete 2014 Proxy Statement. On February 10, 2015, Defendants filed a Motion to Dismiss the Second Amended and Supplemented Complaint, which is still pending. The Company denies any liability and intends to defend the action vigorously.

The Company is involved in various other claims and legal actions arising in the ordinary course of business. In the opinion of management, the ultimate likely disposition of these matters will not have a material adverse effect on the Company's consolidated financial position, results of operations or liquidity.

Lease Commitments—The Company leases office space under non-cancelable operating leases with expiration dates ranging through 2021, with various renewal options. Capital leases range from three to five years and are primarily for computer equipment. There were multiple assets under various individual capital leases at June 30, 2015 and 2014. Rental expense for office

Table of Contents

facilities and certain equipment subject to operating leases for the six months ended June 30, 2015 and 2014 was \$3.3 million and \$3.3 million, respectively.

Self Insurance—For most of the Company's U.S. employees the Company is self-insured for its health insurance program and has a stop loss policy that limits the individual liability to \$120 thousand per person and the aggregate liability to 125% of the expected claims based upon the number of participants and historical claims. As of June 30, 2015, the amount accrued on the Company's Condensed Consolidated Balance Sheet for the self-insured component of the Company's employee health insurance was \$276 thousand. The maximum potential estimated cumulative liability for the annual contract period, which ends in September 2015, is \$2.9 million.

Note 6: Income Taxes

The Company's consolidated world-wide effective tax rate reflects the tax benefits of conducting operating activities in certain foreign jurisdictions where earnings are taxed at rates lower than U.S. statutory rates and where certain components of the Company's income are exempt from taxation. Furthermore, the Company's world-wide product development operations and intellectual property ownership have been centralized into our India and Singapore subsidiaries. Our operations in India benefit from a tax holiday, which affects various operating facilities in that country. The Company has many facilities in India with each one having a different tax holiday expiration date between 2015 and 2018. As such a significant component of the income generated by our India operations, other than passive interest income, is not taxed. After the expiration of the full tax holiday all of the income generated by our India operations will be taxed at 50% of the normal 33.99% corporate tax rate for a period of five years. The Company also has a relatively low income tax rate in Singapore wherein our operations are taxed at a 10% tax rate as a result of concessions granted by the local Singapore Economic Development Board ("EDB") for the benefit of in-country intellectual property owners. The Company has concluded negotiations with the EDB on the terms of the extension for the concessionary 10% income tax rate for a extension period of three years beyond April 2015 till April 2018, and is expecting a formal letter to that effect soon. When the tax rate concession officially expires our Singapore operations will be subject to the prevailing corporate tax rate in Singapore, which is currently 17%.

The Company recognized total income tax expense in the amount of \$3.53 million for the six months ended June 30, 2015. The Company's interim period income tax provisions are based on a current calculated estimate of the effective income tax rate expected to be applicable to the corresponding annual period, after eliminating discrete items unique to the respective interim period being reported. The Company's interim period tax provision, exclusive of discrete items, for the six month period during 2015 reflects an effective tax rate of 8.65%, as compared to the 10.87%, also exclusive of discrete items, for the same period during 2014. The reason for the lower effective rate is due to less taxable income being derived from jurisdictions with higher tax rates.

At June 30, 2015, the Company had remaining available domestic net operating loss ("NOL") carry-forwards of approximately \$40.8 million which are available to offset future U.S. federal and certain state income taxes. In addition the Company has approximately \$41.3 million of NOL's available in the United Kingdom related to the 2013 acquisition of Qatarlyst to offset future taxable income in that country. There is currently a full valuation allowance set up against 100% of these NOL's in the United Kingdom. The Company reviews its NOL positions to validate that all NOL carry-forwards will be utilized before they begin to expire in 2020.

The Company and its subsidiaries file income tax returns in the U.S. federal jurisdiction, and various states and foreign jurisdictions in which it conducts operations or has nexus. With the exception of NOL carry forwards, the Company is no longer subject to U.S. federal or state tax examinations by tax authorities for years before 2013. Regarding our foreign operations as of December 31, 2014, the tax years that remain open and possibly subject to examination by the tax authorities in those jurisdictions are Australia (2008 to 2013), Singapore and Brazil (2008 to 2013), New Zealand (2010 to 2013), and India (2009 to 2013).

Accounting for Uncertainty in Income Taxes—The Company has applied the FASB's accounting guidance on accounting for uncertain income tax positions. As of June 30, 2015 the Company's Condensed Consolidated Balance Sheet includes a liability of \$3.13 million for unrecognized tax benefits which is included in other long term liabilities

before applying the offset provision required by the application of Notice 2013-11. During the six months ended June 30, 2015 there was \$108 thousand in additions to this liability reserve. A reconciliation of the beginning and ending amounts of the Company's liability reserves for unrecognized tax benefits is as follows:

Table of Contents

| | June 30, 2015 | December 31, 2014 |
|---|----------------|-------------------|
| | (in thousands) | |
| Beginning Balance | \$3,020 | \$12,742 |
| Additions for tax positions related to current year | _ | 451 |
| Additions for tax positions of prior years | 108 | 9,348 |
| Reductions for tax position of prior years | _ | (19,521) |
| Ending Balance | \$3,128 | \$3,020 |

The Company recognizes interest accrued and penalties related to unrecognized tax benefits as part of income tax expense. As of June 30, 2015 and December 31, 2014 approximately \$788 thousand and \$680 thousand, respectively, of estimated interest and penalties is included in other long term liabilities in the accompanying Condensed Consolidated Balance Sheet, and is part of the balance of the liability for unrecognized tax benefits in the above table.

The Company has applied the new provisions under FAS update No. 2013-11, Presentation of an Unrecognized Tax Benefit When a Net Operating Loss Carryforward, A Similar Tax Loss, or a Tax Credit Carryforward Exists. Under these provisions, an unrecognized tax benefit, or a portion of an unrecognized tax benefit, should be presented in the financial statements as a reduction to a deferred tax asset for a net operating loss carryforward, a similar tax loss, or a tax credit carryforward in most cases. This provision has been applied and \$929 thousand and \$1.14 million of unrecognized tax benefits have been applied against NOL carryforward amounts as of June 30, 2015 and December 31, 2014, respectively.

Note 7: Geographic Information

The Company operates with one reportable segment whose results are regularly reviewed by the Company's chief operating decision maker as to performance and allocation of resources. External customer revenues in the tables below are attributed to a particular country based on whether the customer had a direct contract with the Company which was executed in that particular country for the sale of the Company's products/services with an Ebix subsidiary located in that country.

The following enterprise wide information relates to the Company's geographic locations (all amounts in thousands): As of and for the Six Months Ended June 30, 2015

| As of the fix World's Ended Julie 50, 2015 | | | | | | | | | |
|--|------------------|---------|------------------|-----------|-----------|----------------|----------|----------|-----------|
| | United States | Canada | Latin America | Australia | Singapore | New Zealand | India | Europe | Total |
| External Revenues | \$98,052 | \$2,210 | \$3,000 | \$16,294 | \$2,421 | \$1,209 | \$1,719 | \$3,560 | \$128,465 |
| Long-lived assets | s \$406,544 | \$7,270 | \$7,936 | \$497 | \$68,668 | \$287 | \$39,636 | \$25,754 | \$556,592 |
| As of and for the Six Months Ended June 30, 2014 United Six Latin Six New Six | | | | | | | | | |
| | States | Canada | America | Australia | Singapore | Zealand | India | Europe | Total |
| External Revenues | \$69,260 | \$2,743 | \$2,981 | \$19,310 | \$2,260 | \$1,353 | \$549 | \$4,424 | \$102,880 |
| Long-lived assets | s\$314,673 | \$8,670 | \$11,503 | \$750 | \$68,402 | \$94 | \$37,449 | \$28,816 | \$470,357 |

Note 8: Minority Business Investment

In 2012, Ebix acquired a minority 19.8% interest in CurePet for cash consideration in the amount of \$2.0 million. CurePet is a developmental-stage enterprise that developed an insurance exchange that connects pet owners, referring veterinarians, animal hospitals, academic institutes, and suppliers of medical and general pet supplies, while providing a wide variety of services related to pet insurance to each constituent including practice management, electronic medical records, and billing. The Company had been accounting for its minority investment in CurePet using the cost method. As disclosed in Note 3 "Business Combinations,"

effective January 27, 2014 Ebix acquired the entire business of CurePet in an asset purchase agreement with the total purchase consideration being in the amount of \$6.35 million which included a possible contingent earnout payment of up to \$5.0 million based on earned revenues over the subsequent thirty-six month period following the date of the acquisition. This contingent earnout liability is currently estimated to have a fair value of zero. During the six months ended June 30, 2015 and 2014 the CurePet business generated \$0 and \$125 thousand, respectively, of revenue which is included in the Company's consolidated revenues reported for the same period.

Note 9: Other Liabilities

Other liabilities at June 30, 2015 and December 31, 2014 consisted of the following:

| | June 30, 2015 | December 31, 2014 |
|--|----------------|-------------------|
| | (In thousands) | |
| Reserve for potential uncertain income tax return positions | \$3,128 | \$3,020 |
| Unfavorable lease liability, long term portion | 248 | 294 |
| Portion of an unrecognized tax benefit netted against deferred tax asset for a net operating loss carryforward | \$(929) | \$(1,135) |
| Total | \$2,447 | \$2,179 |

Note 10: Subsequent Events

Repurchases of Common Stock

Since March 31, 2015 and through June 30, 2015 the Company repurchased 349,365 shares of its outstanding common stock for aggregate cash consideration in the amount of \$10.3 million and at an average rate of \$29.36 per share. Subsequent to June 30th and through August 7, 2015 the Company has re-purchased an additional 480,125 shares of its outstanding common stock for aggregate cash consideration in the amount of \$14.7 million and at an average rate of \$30.59 per share. All share repurchases were done in accordance with Rule 10b-18 of the Securities Act of 1934 as to the timing, pricing, and volume of such transactions, and were funded from available cash resources, cash generated from the Company's operating activities, and draws from the Company's revolving line of credit with our syndicated commercial banking facility.

Table of Contents

Item 2: MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

As used herein, the terms "Ebix," "the Company," "we," "our" and "us" refer to Ebix, Inc., a Delaware corporation, and its consolidated subsidiaries as a combined entity, except where it is clear that the terms mean only Ebix, Inc. Safe Harbor for Forward-Looking Statements—This Form 10-Q and certain information incorporated herein by reference contains forward-looking statements and information within the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995, Section 27A of the Securities Act of 1933, and Section 21E of the Securities Exchange Act of 1934. This information includes assumptions made by, and information currently available to management, including statements regarding future economic performance and financial condition, liquidity and capital resources, acceptance of the Company's products by the market, and management's plans and objectives. In addition, certain statements included in this and our future filings with the Securities and Exchange Commission ("SEC"), in press releases, and in oral and written statements made by us or with our approval, which are not statements of historical fact, are forward-looking statements. Words such as "may," "could," "should," "would," "believe," "expect," "anticipate," "estimate," "intend," "seeks," "plan," "project," "continue," "predict," "will," and other words or expressions of s meaning are intended by the Company to identify forward-looking statements, although not all forward-looking statements contain these identifying words. These forward-looking statements are found at various places throughout this report and in the documents incorporated herein by reference. These statements are based on our current expectations about future events or results and information that is currently available to us, involve assumptions, risks, and uncertainties, and speak only as of the date on which such statements are made. Our actual results may differ materially from those expressed or implied in these forward-looking statements. Factors

Our actual results may differ materially from those expressed or implied in these forward-looking statements. Factors that may cause such a difference, include, but are not limited to those discussed and identified in Part II, Item 1A "Risk Factors" for the six months ended June 30, 2015 in this Form 10-Q, and in Part I, Item 1A, "Risk Factors" in our 2014 Form 10-K which is incorporated by reference herein, as well as: the risk of an unfavorable outcome of the pending governmental investigations, and the reputational harm caused by such investigations and lawsuits; the willingness of independent insurance agencies to outsource their computer and other processing needs to third parties; pricing and other competitive pressures and the Company's ability to gain or maintain share of sales as a result of actions by competitors and others; changes in estimates in critical accounting judgments; changes in or failure to comply with laws and regulations, including accounting standards, taxation requirements (including tax rate changes, new tax laws and revised tax interpretations) in domestic or foreign jurisdictions; exchange rate fluctuations and other risks associated with investments and operations in foreign countries (particularly in India, Singapore, Australia, Latin America, and Europe wherein we have significant and/or growing operations); equity markets, including market disruptions and significant interest rate fluctuations, which may impede our access to, or increase the cost of, external financing; and international conflict, including terrorist acts. The Company undertakes no obligation to update any such factors, or to publicly announce the results of, or changes to any of the forward-looking statements contained herein to reflect future events, developments, changed circumstances, or for any other reason.

Other important factors that could cause actual results to differ materially from those in our specific forward-looking statements included in this Form 10-Q include, but are not limited to, the following:

Regarding Note 4 of the Notes to the Condensed Consolidated Financial Statements, and our future liquidity needs discussed under "Liquidity and Financial Condition" as pertaining to our ability to generate cash from operating activities and any declines in our credit ratings or financial condition which could restrict our access to the capital markets or materially increase our financing costs;

With respect to Note 5 of the Notes to the Condensed Consolidated Financial Statements, "Commitments and Contingencies", and "Contractual Obligations and Commercial Commitments" in MD&A, as regarding to changes in the market value of our assets or the ultimate actual cost of our contractual commitments and contingencies; With respect to Note 3 of the Condensed Notes to the Condensed Consolidated Financial Statements as pertaining to the business acquisitions we have made and our ability to efficiently and effectively integrate acquired business operations;

•

With respect this Management Discussion & Analysis of Financial Condition and Results of Operation and the analysis of the three and six month revenue trends including the actual realized level of demand for our products during the immediately foreseeable future.

Readers should carefully review the disclosures and the risk factors described in this and other documents we file from time to time with the SEC, including future reports on Forms 10-Q and 8-K, and any amendments thereto. You may obtain our SEC filings at our website, www.ebix.com under the "Investor Information" section, or over the Internet at the SEC's website, www.sec.gov.

Table of Contents

The following information should be read in conjunction with the unaudited condensed consolidated financial statements and the notes thereto included in Part 1, Item 1 of this Quarterly Report, and the audited consolidated financial statements and notes thereto and Management's Discussion and Analysis of Financial Condition and Results of Operations contained in the Company's Annual Report on Form 10-K for the year ended December 31, 2014.

Company Overview

Ebix, Inc. is a leading international supplier of software and e-commerce solutions to the insurance industry. Ebix provides a variety of application software products for the insurance industry ranging from carrier systems, agency systems and data exchanges to custom software development for all entities involved in insurance and financial services. Our goal is to be the leading provider of back-end insurance transaction processing in the world. The Company's vision is to focus on the convergence of technology platforms for all insurance channels, processes and entities in a manner such that data seamlessly flows once a data entry has been made. Our customers include many of the top insurance and financial sector companies in the world.

The insurance industry continues to undergo significant consolidation driven by the need for, and benefits from, economies of scale and scope in providing insurance services in a competitive environment. Such consolidation has involved both insurance carriers and insurance brokers and is directly impacting the manner in which insurance products are distributed. Furthermore the insurance industry has particularly experienced a steady increase in initiatives designed to reduce paper-based processes and to improve efficiency both at the back-end and consumer end sides. Management believes the insurance industry will continue to experience significant change and increased efficiencies through online exchanges, as the transition from paper-based processes are increasingly becoming the norm across world insurance markets. Changes in the insurance industry are likely to create new opportunities for the Company.

Ebix strives to work collaboratively with clients to develop innovative technology strategies and solutions that address specific business challenges. Ebix combines the newest technologies with its capabilities in consulting, systems design and integration, IT and business process outsourcing, applications software, and Web and application hosting to meet the individual needs of insurance providers and related entities. We intend to continue to expand both organically and through strategic business acquisitions.

Offices and Geographic Information

The Company has its worldwide headquarters in Atlanta, Georgia with its international operations being managed from its Singapore offices, and it also has domestic operations in Santa Barbara, Pasadena, and Hemet, California; Miami, Florida; Pittsburgh, Pennsylvania; Salt Lake City, Utah; Grove City, Ohio; Bohemia, New York; Norwalk and New Britain, Connecticut; Portland, Michigan; Birmingham, Alabama; Iselin, New Jersey as well as an additional operations office in Atlanta, Georgia. The Company also has operating facilities and offices in Australia, Brazil, Thailand, New Zealand, the United Kingdom, Canada and India. In these operating offices, Ebix employs insurance and technology professionals who provide products, services, support and consultancy to thousands of customers across six continents.

Results of Operations — Three Months Ended June 30, 2015 and 2014

Operating Revenue

The Company derives its revenues primarily from subscription and transaction fees pertaining to services delivered over our exchanges or from our ASP platforms, fees for business process outsourcing services, and fees for software development projects including associated fees for consulting, implementation, training, and project management provided to customers with installed systems. International revenue accounted for 23.7% and 32.7% of the Company's total revenue for the six months ended June 30, 2015 and 2014, respectively.

Ebix's revenue streams come from four product channels. Presented in the table below is the breakout of our revenues for each of those product channels for the three and six month periods ended June 30, 2015 and 2014.

Table of Contents

| | Three Months Ended | | Six Months Ended | |
|-----------------------------------|--------------------|----------|------------------|-----------|
| | June 30, | | June 30, | |
| (dollar amounts in thousands) | 2015 | 2014 | 2015 | 2014 |
| Exchanges | \$46,825 | \$41,350 | \$93,503 | \$83,455 |
| Broker Systems | 3,519 | 4,865 | 7,255 | 9,351 |
| Risk Compliance Solutions ("RCS") | 13,289 | 3,652 | 25,464 | 7,077 |
| Carrier Systems | 1,079 | 1,609 | 2,243 | 2,997 |
| Totals | \$64,712 | \$51,476 | \$128,465 | \$102,880 |

During the three months ended June 30, 2015 our total operating revenues increased \$13.2 million or 26%, to \$64.7 million as compared to \$51.5 million during the second quarter of 2014. Revenues increased as a result of revenue growth from Life, Annuity, Underwriting, and CRM products and services, in addition to revenue growth generated from the Company's 2014 acquisitions of HealthCare Magic, Vertex, and Oakstone and the 2015 acquisition of PB Systems, partially offset by the drop in revenue from international locations due to the strengthening of the U.S. dollar and a modest decrease in revenues from the Company's pharmaceutical and P&C carrier backend system operations. The adverse impact from fluctuations of the exchange rates for the foreign currencies in the countries in which we conduct operations which in the aggregate reduced reported revenues 2nd quarter 2015 by \$2.7 million.

With respect to business acquisitions completed during the years 2015 and 2014 on a pro forma basis, as disclosed in the table in Note 3 "Pro Forma Financial Information" to the enclosed Condensed Consolidated Financial Statements, combined revenues decreased \$1.5 million or 2.2% for Q2 2015 versus the Q2 2014 whereas correspondingly, the reported revenue for the three months ended June 30, 2015 increased by \$13.2 million or 25.7% from the reported revenue during the same period in 2014. The 2015 and 2014 pro forma financial information assumes that all business acquisitions made during this period were made on January 1, 2014, whereas the Company's reported financial statements for Q2 2015 and Q2 2014 only includes the revenues from these businesses since the effective date that they were acquired by Ebix, being January 2014 for CurePet, May 2014 for HealthCare Magic, October 2014 for Vertex, December 2014 for Oakstone and i3, March 2015 for Via Media Health, and June 2015 for PB Systems. The 2014 pro forma financial information includes a full three months of results for CurePet and HealthCare Magic as if they had been acquired on January 1, 2014.

The above referenced pro forma information and the relative comparative change in pro forma and reported revenues are based on the following premises:

2015 and 2014 pro forma revenue contains actual revenue of the acquired entities before acquisition date, as reported by the sellers, as well as actual revenue of the acquired entities after acquisition. Whereas the reported growth in revenues of the acquired entities after acquisition date are only reflected for the period after their acquisition.

• Revenue billed to existing clients from the cross selling of acquired products has been assigned to the acquired section of our business.

Any existing products sold to new customers obtained through a newly acquired customer base, are assigned to the acquired section of our business.

2014 pro forma revenues include revenues from some product lines whose sales were discontinued after the acquisition date and revenues from some customers whose contracts were discontinued for efficiency and/or competitive reasons.

Cost of Services Provided

Costs of services provided, which include costs associated with maintenance, support, call center, consulting, implementation and training services, increased \$8.7 million or 88%, to \$18.7 million in the second quarter of 2015 as compared to \$10.0 million in the second quarter of 2014. This increase is primarily due to greater personnel, facility, and external consulting costs associated with the Q4'2014 acquisitions of Oakstone, i3, and Vertex, and our Q2 2015 acquisition of PB Systems.

Product Development Expenses

The Company's product development efforts are focused on the development of new processing technologies, software, systems and related services for use by insurance carriers, brokers and agents, and the development of new data exchanges for use in the domestic and international insurance markets. Product development expenses increased \$530 thousand or 8%, to \$7.3

Table of Contents

million during the second quarter of 2015 as compared to \$6.8 million during the second quarter of 2014. This increase is attributable to additional personnel costs for our growing employee base in our product development facilities in India

Sales and Marketing Expenses

Sales and marketing expenses decreased \$173 thousand or 5%, to \$3.61 million in the second quarter of 2015 as compared to \$3.78 million in the second quarter of 2014. This decrease is due to lower personnel and related facilities costs related to the reduced staffing associated with continued de-emphasis on certain products generating relatively low operating margins.

General and Administrative Expenses

General and administrative expenses increased by \$1.1 million or 10%, to \$12.12 million in the second quarter of 2015 as compared to \$11.07 million in the second quarter of 2014. This comparative year over year net increase in general and administrative expenses is associated with recognized performance bonus compensation expense, and additional corporate and employee health insurance costs.

Amortization and Depreciation Expenses

Amortization and depreciation expenses increased \$129 thousand or 5% to \$2.57 million in the second quarter of 2015 as compared to \$2.44 million in the second quarter of 2014, due to additional depreciation expense being recognized for newly acquired capital equipment and with respect to build out additions for our new corporate headquarters office facilities.

Interest Income

Interest income decreased \$86 thousand or 66%, to \$44 thousand in the second quarter of 2015 as compared to \$130 thousand in the second quarter of 2014. Interest income decreased as a result of the year over year decrease in average interested bearing cash balances which decreased 40% to \$27.9 million during Q2 2015 from \$46.5 million during Q2 2014.

Interest Expense

Income Taxes

Interest expense increased \$414 thousand or 196%, to \$625 thousand in the second quarter of 2015 as compared to \$211 thousand in the second quarter of 2014. Interest expense increased due to the increase in the average outstanding balance on our commercial banking credit facilities, which increased 767% to \$139.5 million during Q2 2015 from \$16.1 million during Q2 2014.

Foreign Currency Exchange Gain

Net foreign currency exchange gains for the three months ended June 30, 2015 in the amount of \$330 thousand and consists of \$38 thousand of gains realized upon the settlement of transactions denominated in currencies other than the functional currency of the respective operating division recognizing the transaction, and \$292 thousand of gains recognized upon the remeasurement of certain outstanding receivables or payables denominated in currencies other than the functional currency of the respective operating division recording the instrument.

The Company's consolidated world-wide effective tax rate reflects the tax benefits of conducting operating activities in certain foreign jurisdictions where earnings are taxed at rates lower than U.S. statutory rates and where certain components of the Company's income are exempt from taxation. Furthermore, the Company's product development operations and intellectual property ownership have been centralized into our India and Singapore subsidiaries. Our operations in India benefit from a tax holiday, which affects various operating facilities in that country. The tax holiday expired for one of our facilities in April of 2014 for one other of our facilities in April 2015, and will expire for the remaining of facilities in India in the years 2016 through 2020. As such, a significant component of the income generated by our India operations, other than passive interest income, is not taxed. After the expiration of the full tax holidays the income is taxed at 50% of the normal 33.99% corporate tax rate for a period of five years. The Company also has a relatively low income tax rate in Singapore wherein our operations are taxed at a 10% tax rate as a result of concessions granted by the local Singapore Economic Development Board for the benefit of in-country intellectual property owners. The Company has concluded negotiations on the terms of the extension for the concessionary 10% income tax rate for a extension period of three years beyond April 2015 till April 2018, and is expecting a formal letter to that effect soon. When the tax rate concession officially expires our Singapore operations will be subject to

the prevailing corporate tax rate in Singapore, which is currently 17%.

The Company recognized total income tax expense of \$1.1 million for the three months ended June 30, 2015, as compared to \$3.3 million for the three months ended June 30, 2014. The Company's interim period income tax provisions are based on our

Table of Contents

current calculated estimate of the effective income tax rate expected to be applicable to the corresponding annual period after eliminating any discrete items unique to the respective interim period being reported. The Company's interim period tax provision for the three month period ending June 30, 2015 reflects a consolidated world-wide effective tax rate of 8.65%, as compared to the 10.87% for the same period in 2014. The effective rate decreased due to less attributable taxable income from jurisdictions with higher tax rates.

Results of Operations — Six Months Ended June 30, 2015 and 2014

Operating Revenue

During the six months ended June 30, 2015 our total operating revenues increased \$25.6 million or 25%, to \$128.5 million as compared to \$102.9 million during the same period of 2014. Revenues increased as a result of revenue growth from Life, Annuity, Underwriting, and CRM products and services, in addition to revenue growth generated from the Company's 2014 acquisitions of HealthCare Magic, Vertex, and Oakstone and the 2015 acquisition of PB Systems, partially offset by the drop in revenue from international locations due to the strengthening of the U.S. dollar. The adverse impact from fluctuations of the exchange rates for the foreign currencies in the countries in which we conduct operations which in the aggregate reduced reported revenues by \$4.6 million.

With respect to business acquisitions completed during the years 2015 and 2014 on a pro forma basis, as disclosed in the table in Note 3 "Pro Forma Financial Information" to the enclosed Condensed Consolidated Financial Statements, combined revenues decreased by \$4.3 million or 3.1% decrease for the six months ending June 30, 2015 versus the the six months ending June 30, 2014 whereas correspondingly, the reported revenue for the six months ended June 30, 2015 increased by \$25.6 million or 24.9% from the reported revenue during the same period in 2014. The 2015 and 2014 pro forma financial information assumes that all business acquisitions were made on January 1, 2014, whereas the Company's reported financial statements for YTD June 2015 and YTD June 2014 only includes the revenues from these businesses since the effective date that they were acquired by Ebix, being January 2014 for CurePet, May 2014 for HealthCare Magic, October 2014 for Vertex, December 2014 for Oakstone and i3, March 2015 for Via Media Health, and June 2015 for PB Systems. The 2014 pro forma financial information includes a full six months of results for CurePet and HealthCare Magic as if they had been acquired on January 1, 2014.

The above referenced pro forma information and the relative comparative change in pro forma and reported revenues are based on the following premises:

2015 and 2014 pro forma revenue contains actual revenue of the acquired entities before acquisition date, as reported by the sellers, as well as actual revenue of the acquired entities after acquisition. Whereas the reported growth in revenues of the acquired entities after acquisition date are only reflected for the period after their acquisition.

• Revenue billed to existing clients from the cross selling of acquired products has been assigned to the acquired section of our business.

Any existing products sold to new customers obtained through a newly acquired customer base, are assigned to the acquired section of our business.

2014 pro forma revenues include revenues from some product lines whose sales were discontinued after the acquisition date and revenues from some customers whose contracts were discontinued for efficiency and/or competitive reasons.

Cost of Services Provided

Costs of services provided, which include costs associated with maintenance, support, call center, consulting, implementation and training services, increased \$18.6 million or 95%, to \$38.2 million in the six months ended June 30, 2015 as compared to \$19.6 million in the same period of 2014. This increase is primarily due to greater personnel, facility, office related, and external consulting costs associated with the Q4 2014 acquisitions of Oakstone, i3, and Vertex, and the Q2 2015 acquisition of PB Systems.

Product Development Expenses

The Company's product development efforts are focused on the development of new processing technologies, software, systems and related services. Product development expenses increased \$884 thousand or 7%, to \$14.3 million during the six months ended June 30, 2015 as compared to \$13.5 million during the same period of 2014. This

increase is primarily due to additional personnel costs for our growing employee base in our product development facilities in India.

Table of Contents

Sales and Marketing Expenses

Sales and marketing expenses decreased slightly \$95 thousand or 1%, to \$7.0 million during the six months ended June 30, 2015 as compared to \$7.1 million during the same period of 2014. This decrease is due to lower personnel and related facilities costs related to the reduced staffing associated with the ongoing de-emphasis on certain products generating relatively low operating margins.

General and Administrative Expenses

General and administrative expenses increased by \$2.0 million or 9%, to \$22.9 million during the six months ended June 30, 2015 as compared to \$20.9 million during the same period of 2014. This comparative year over year net increase in general and administrative expenses is associated with additional personnel costs and with staffing absorbed with the Q4'2014 acquisitions of Oakstone, i3, and Vertex, and the Q2 2015 acquisition of PB Systems and with additional corporate and employee health insurance costs.

Amortization and Depreciation Expenses

Amortization and depreciation expenses increased \$175 thousand or 3% to \$5.2 million during the six months ended June 30, 2015 as compared to \$5.0 million during the same period of 2014, due to additional depreciation expense being recognized for newly acquired capital equipment and with respect to build out additions for our new corporate headquarters office facilities.

Interest Income

Interest income decreased \$160 thousand or 60%, to \$105 thousand during the six months ended June 30, 2015 as compared to \$265 thousand during the same period of 2014. Interest income decreased as a result of the year over year decrease in average interested bearing cash balances which decreased 19% to \$39.8 million during Q2 of 2015 from \$49.1 million during Q2 2014.

Interest Expense

Interest expense increased \$886 thousand or 193%, to \$1.3 million during the six months ended June 30, 2015 as compared to \$458 thousand during the same period of 2014. Interest expense increased due to the increase in the average outstanding balance on our commercial banking credit facilities, which increased 588% to \$133.5 million during this six month period of 2015 from \$19.4 million during during this six month period of 2015.

Foreign Currency Exchange Gain

Net foreign currency exchange gains for the three months ended June 30, 2015 in the amount of \$1.2 million and consists of \$471 thousand of gains realized upon the settlement of transactions denominated in currencies other than the functional currency of the respective operating division recognizing the transaction, and \$751 thousand of gains recognized upon the remeasurement of certain outstanding receivables or payables denominated in currencies other than the functional currency of the respective operating division recording the instrument.

Income Taxes

The Company's consolidated world-wide effective tax rate reflects the tax benefits of conducting operating activities in certain foreign jurisdictions where earnings are taxed at rates lower than U.S. statutory rates and where certain components of the Company's income are exempt from taxation. Furthermore, the Company's product development operations and intellectual property ownership have been centralized into our India and Singapore subsidiaries. Our operations in India benefit from a tax holiday, which affects various operating facilities in that country. The tax holiday expired for one of our facilities in April of 2014 for one other of our facilities in April 2015, and will expire for the remaining of facilities in India in the years 2016 through 2020. As such a significant component of the income generated by our India operations, other than passive interest income, is not taxed. After the expiration of the full tax holidays the income is taxed at 50% of the normal 33.99% corporate tax rate for a period of five years. The Company also has a relatively low income tax rate in Singapore wherein our operations are taxed at a 10% tax rate as a result of concessions granted by the local Singapore Economic Development Board for the benefit of in-country intellectual property owners. The Company has concluded negotiations on the terms of the extension for the 10% concessionary income tax rate for a extension period of three years beyond April 2015 till April 2018, and is expecting a formal letter to that effect soon. When the tax rate concession officially expires our Singapore operations will be subject to the prevailing corporate tax rate in Singapore, which is currently 17%.

The Company recognized total income tax expense of \$3.5 million for the six months ended June 30, 2015, as compared to \$7.5 million during the same period of 2014. The Company's interim period income tax provisions are based on our current

Table of Contents

calculated estimate of the effective income tax rate expected to be applicable to the corresponding annual period after eliminating discrete items unique to the respective interim period being reported. The Company's interim period tax provision for the six month period ending June 30, 2015 reflects an effective tax rate of 8.65%, as compared to the 10.87% for the same period in 2014. The effective rate decreased due to less taxable income from jurisdictions with higher tax rates.

Liquidity and Capital Resources

The Company's ability to generate significant cash flows from ongoing operating activities is one of our fundamental financial strengths. Our principal sources of liquidity are the cash flows provided by the Company's operating activities, our commercial banking credit facility, and cash and cash equivalents on hand. Due to the effect of temporary or timing differences resulting from the differing treatment of items for tax and accounting purposes (including the treatment of net operating loss carryforwards and minimum alternative tax obligations in the U.S. and India, respectively), future cash outlays for income taxes are expected to exceed income tax expense. We intend to utilize cash flows generated by our operations, in combination with our commercial bank credit facility, and the possible issuance of additional equity or debt securities, to fund capital expenditures and organic growth initiatives, to make strategic accretive business acquisitions in the insurance services sector, and to re-purchase shares of our common stock as market conditions warrant.

We believe that anticipated cash flows provided by our operating activities, together with current cash and cash equivalent balances, access to our credit facilities, and access to the capital markets, if required and available, will be sufficient to meet our projected cash requirements for the foreseeable future, although any projections of future cash needs, cash flows, and the condition of the capital markets in general, as to the availability of debt and equity financing, are subject to substantial uncertainty.

Our cash and cash equivalents were \$27.4 million and \$52.3 million at June 30, 2015 and December 31, 2014, respectively. The free flow of cash from certain countries where we hold significant cash balances may be subject to repatriation tax effects and other restrictions. Specifically the repatriation of earnings from some of our foreign subsidiaries could result in the application of withholding taxes at source as well as a tax at the U.S. parent level upon receipt of repatriated amounts. The approximate cash, cash equivalents, and short-term investments balances held in our domestic U.S. operations and each of our foreign subsidiaries as of August 7, 2015 are presented in the table below (figures denominated in thousands):

| | United States | Canada | Latin America | Australia | Singapore | New Zealand | India | Europe | Sweden | Total |
|-------------------------|---------------|---------|------------------|-----------|-----------|----------------|---------|---------|--------|----------|
| Cash and ST investments | \$22,122 | \$2,801 | \$1,061 | \$6,606 | \$1,114 | \$1,231 | \$5,725 | \$1,750 | \$12 | \$42,422 |

Our current ratio increased moderately to 1.66 at June 30, 2015 from 1.49 at December 31, 2014 and our working capital position accordingly has also increased to \$34.8 million at June 30, 2015 from \$34.1 million at the end of the 2014. Our short-term liquidity has improved due to increased outstanding trade accounts receivable, and the reduction in accounts payable and accrued liabilities primarily as a result of the cash payment of \$20.5 million (including interest of \$1.6 million) stemming from the settlement and resolution of the Internal Revenue Service's previously disclosed audit of Ebix's income tax returns for the taxable years 2008 through 2012.

We believe that Ebix's ability to generate sustainable and robust cash flows from operations will enable the Company to continue to fund its current liabilities from current assets including available cash balances for the foreseeable future.

Business Combinations

The Company seeks to execute accretive business acquisitions in combination with organic growth initiatives as part of its comprehensive business growth and expansion strategy. The Company looks to acquire businesses that are complementary to Ebix's existing products and services. During the six months ended June 30, 2015, the Company completed two business acquisition, as described immediately below.

The Company acquired PB Systems, Inc. and PB Systems Private Limited (together being "PB Systems"), effective June 1, 2015. PB Systems develops and implements software solutions for insurance clients. Ebix acquired PB Systems for upfront cash consideration in the amount of \$12.4 million, plus a possible future one time contingent earnout payment of up to \$8.0 million based on earned revenues over the subsequent twenty-four month period following the effective date of the acquisition. The valuation and purchase price allocation for the PB Systems acquisition is preliminary and will be finalized prior to December 31, 2015.

Table of Contents

Via Media Health Communications Private Limited ("Via Media Health") was acquired effective March 1, 2015. Via Media Health is one of India's leading health content and communication companies. Ebix acquired Via Media Health for upfront cash consideration in the amount of \$1.0 million, plus a possible future one time contingent earnout payment of up to \$372 thousand based on earned revenues over the subsequent twelve month period following the effective date of the acquisition, and a possible one time future performance bonus depending upon revenue growth realized in the business over the subsequent twenty-four month period following the effective date of the acquisition. The valuation and purchase price allocation for the Via Media Health acquisition remains preliminary and will be finalized prior to September 30, 2015.

Effective December 2, 2014, Ebix acquired Oakstone Publishing, LLC ("Oakstone") in a membership interest purchase agreement for total net cash consideration in the amount of \$23.72 million (\$31.37 million less a closing net working capital adjustment of \$7.65 million). Oakstone is leading provider of continuing education, certification materials for physicians, dentists and allied healthcare professionals, as well as wellness resources for various organizations. Ebix acquired all of the outstanding membership interests of Oakstone and funded the purchase using a mix of internal cash reserves and the bank credit line available to Ebix. The Company accounted for this acquisition by recording \$28.8 million of goodwill, \$1.7 million of intangible assets pertaining to customer relationships, \$501 thousand of intangible assets pertaining to acquired technology, and a \$6.5 million deferred revenue liability. The valuation and purchase price allocation for the Oakstone acquisition remains preliminary and will be finalized prior to September 30, 2015.

On December 1, 2014, Ebix acquired the DCM Group Inc. (d.b.a. i3 Software) ("i3") in an asset purchase agreement for total cash consideration in the amount of \$2 million and a possible contingent earnout of up to \$4 million based on earned revenues over the subsequent twenty-four month period following the date of the acquisition. i3 is a provider of software services and solutions to the insurance industry. Ebix acquired all of the assets of i3 and funded the purchase using internal cash reserves. The Company accounted for this acquisition by recording \$3.7 million of goodwill, \$225 thousand of intangible assets pertaining to customer relationships, and \$75 thousand of intangible assets pertaining to acquired technology. The valuation and purchase price allocation for the i3 acquisition remains preliminary and will be finalized prior to September 30, 2015.

On November 3, 2014, Ebix acquired Vertex, Incorporated ("Vertex"), with an effective date of October 1, 2014, in a share purchase agreement for total cash purchase consideration in the amount of \$27.25 million and a possible contingent earnout of \$2 million based on earned revenues over the subsequent twenty-four month period following the date of the acquisition. Vertex is a specialized software and services firm focused primarily on the life and annuity insurance marketplace since 1991. Ebix acquired all of the outstanding capital stock of Vertex and funded the purchase using a mix of internal cash reserves and the bank credit line available to Ebix. The Company accounted for this acquisition by recording \$27.7 million of goodwill, \$2.5 million of intangible assets pertaining to customer relationships, and \$235 thousand of intangible assets pertaining to acquired technology. The valuation and purchase price allocation for the Vertex acquisition remains preliminary and will be finalized prior to September 30, 2015.

On May 21, 2014, Ebix acquired HealthCare Magic Private Limited ("HealthCare Magic"), a medical advisory service with an online network of approximately fifteen thousand General Physicians and Surgeons spread across fifty specialties including alternative medicine. The Company acquired HealthCare Magic for aggregate cash consideration in the amount of \$6.0 million plus a possible future one time contingent earnout payment of up to \$12.36 million based on earned revenues over the subsequent twenty-four month period following the effective date of the acquisition. This contingent earnout liability is currently estimated to have a fair value of \$596 thousand. The Company funded the HealthCare Magic acquisition from available cash reserves on hand. The Company accounted for this acquisition by recording \$5.6 million of goodwill, \$452 thousand of intangible assets pertaining to customer relationships, \$100 thousand of intangible assets pertaining to acquired technology, \$59 thousand on intangible assets pertaining to trademarks and tradenames, and \$226 thousand of intangible assets pertaining to non-compete agreements.

On January 27, 2014, Ebix acquired CurePet. CurePet was a developmental-stage enterprise that developed an insurance exchange that connects pet owners, referring veterinarians, animal hospitals, academic institutes, and suppliers of medical and general pet supplies, while providing a wide variety of services related to pet insurance to each constituent including practice management, electronic medical records, and billing. Previously Ebix had a minority investment in CurePet. Ebix acquired the entire business of CurePet in an asset purchase agreement with total purchase consideration being \$6.35 million which includes a possible future one time contingent earnout payment of up to \$5.0 million based on earned revenues over the subsequent thirty-six month period following the effective date of the acquisition. This contingent earnout liability is currently estimated to have a fair value of zero. Additional required cash consideration of \$1.35 million was offset against open accounts receivable balances due to the Company from CurePet, and no actual cash outlay was made by the Company.

A significant component of the purchase price consideration for many of the Company's business acquisitions is a potential subsequent cash earnout based on reaching certain specified future revenue targets. The Company recognizes these potential

Table of Contents

obligations as contingent liabilities. These contingent consideration liabilities are recorded at fair value on the acquisition date and are re-measured quarterly based on the then assessed fair value and adjusted if necessary. As of June 30, 2015, the total of these contingent liabilities was \$10.08 million, of which \$8.19 million is reported in long-term liabilities, and \$1,887 thousand was included in current liabilities in the Company's Condensed Consolidated Balance Sheet. As of December 31, 2014 the total of these contingent liabilities was \$5.4 million, of which \$4.5 million is reported in long-term liabilities, and \$887 thousand was included in current liabilities in the Company's Condensed Consolidated Balance Sheet.

Operating Activities

Net cash used by our operating activities was \$10.2 million for the six months ended June 30, 2015. The primary components of the cash used in operations during the six months period consisted of net income of \$37.4 million, net of \$(0.9) million of unrealized foreign currency exchange gains, \$5.2 million of depreciation and amortization, and \$0.8 million of non-cash share-based compensation. Partially offsetting this net cash inflow was \$(32.3) million of working capital requirements primarily associated with increased outstanding trade accounts receivable and the cash payment of the \$20.5 million assessment (including interest of \$1.6 million) stemming from the resolution of the Internal Revenue Service's previously disclosed audit of Ebix's income tax returns for the taxable years 2008 through 2012.

Net cash provided by our operating activities was \$28.6 million for the six months ended June 30, 2014. The primary components of the cash provided by operations during the six months period consisted of net income of \$29.0 million, net of \$0.2 million of net non-cash gains recognized on derivative instruments and foreign currency exchange, \$5.0 million of depreciation and amortization, \$(1.8) million of non-cash gains associated with the reduction to acquisition related earnout contingent liabilities, \$(0.5) million of working capital requirements primarily associated with increased outstanding trade accounts receivable, reduced trade payables, and reduced deferred revenues, and a \$(4.2) million payment in satisfaction of the securities litigation settlement obligation, and \$0.9 million of non-cash share-based compensation.

Investing Activities

Net cash used for investing activities during the six months ended June 30, 2015 was \$23.5 million, of which \$11.5 million was used for the acquisition of P.B. Systems (net of cash acquired), \$8.7 million was used for buying additional land adjacent to, and the continued interior build out of our new global corporate headquarters in the Atlanta metropolitan area, \$1.0 million was used for the acquisition of Via Media Health, and \$1.6 million of capital expenditures pertaining to the enhancement of our technology platforms and the purchases of operating equipment to support our expanding operations, and \$704 thousand for the purchase of marketable securities (specifically bank certificates of deposit).

Net cash used for investing activities during the six months ended June 30, 2014 was \$22.5 million, of which of \$12.5 million was used for the acquisition of a building and land for our new global corporate headquarters in Johns Creek, Georgia, \$5.9 million was used for the acquisition of Healthcare Magic, \$2.3 million was used for the payment of an earnout obligation in connection with our 2012 acquisition of Taimma, \$1.4 million of capital expenditures, and \$0.6 million for the purchase of marketable securities (specifically bank certificates of deposit).

Financing Activities

During the six months ended June 30, 2015 net cash used by financing activities was \$10.5 million which consisted of \$5.4 million used to pay quarterly dividends to our common stockholders, \$34.5 million used to repurchase 1.34 million shares of our common stock, and \$624 thousand used to make principal payments on long-term debt and capital lease obligations. Partially offsetting these financing cash outflows was \$30.0 million provided by draws off of the Company's revolving credit facility with Regions.

During the six months ended June 30, 2014 net cash used by financing activities was \$30.7 million which primarily consisted of a \$15.0 million principal payment against our revolving line of credit, \$4.8 million of principal repayments against our then term loan facility with Citibank, \$5.8 million used to pay quarterly dividends to our common stockholders, \$2.2 million used to repurchase 137 thousand shares of our common stock, \$3.2 million pertained to the excess tax benefits associated with share-based compensation and \$424 thousand used to make principal payments on long-term debt and capital lease obligations. Partially offsetting these financing cash outflows was \$788 thousand of proceeds from the exercise of stock options.

Commercial Bank Financing Facility

On February 3, 2015 the Company and certain of its subsidiaries entered into the First Amendment to the Regions Secured Credit Facility, dated August 5, 2014, among the Company, Regions as Administrative Agent, with Regions, MUFG Union Bank

Table of Contents

N.A., and Silicon Valley Bank as joint lenders. The First Amendment amends the Credit Agreement by increasing the maximum amount by which the Aggregate Revolving Commitments may be increased to \$90 million from the pre-existing limit of \$50 million, increases the amount of base facility to \$190 million from the pre-existing amount of \$150 million, which together with the \$50 million accordion feature increases the total Credit Agreement capacity amount to \$240 million from the prior amount of \$200 million, and expands the syndicated bank group to four participants by adding Fifth Third Bank.

On August 5, 2014, Ebix entered into a credit agreement providing for a \$150 million secured syndicated credit facility (the "Regions Secured Credit Facility") with Regions as administrative agent and Regions with MUFG Union Bank N.A., and Silicon Valley Bank as joint lenders. The financing is comprised of a five-year, \$150 million secured revolving credit facility, with an option to expand to \$200 million upon request and with additional lender participation. This new \$150 million credit facility with Regions, as administrative agent, replaces the former syndicated \$100 million facility that the Company had in place with Citi Bank, N.A. which was paid in full upon the undertaking of this new loan facility with Regions. The interest rate applicable to the Regions Secured Credit Facility is LIBOR plus 1.5%. Under the Regions Secured Credit Facility the maximum interest rate that could be charged depending upon the Company's leverage ratio is LIBOR plus 2.25%. The underlying financing agreement contains financial covenants regarding the Company's annualized fixed charge coverage ratio and leverage ratio, as well as certain restrictive covenants pertaining to such matters as the incurrence of new debt and the consummation of new business acquisitions. The Company currently is in compliance with all such financial and restrictive covenants.

At June 30, 2015, the outstanding balance on the revolving line of credit under the Regions Secured Syndicated Credit Facility was \$150.5 million and the facility carried an interest rate of 1.94%. During the six months ended June 30, 2015, no payments were made against the revolving line of credit. The revolving line of credit balance is included in the long-term liabilities section of the Condensed Consolidated Balance Sheets. During the six months period ended June 30, 2015, the average and maximum outstanding balances on our revolving line of credit facilities were \$133.5 million and \$150.5 million, respectively.

Off-Balance Sheet Arrangements

We do not engage in off -balance sheet financing arrangements.

Recent Accounting Pronouncements

For information about new accounting pronouncements and the potential impact on our Consolidated Financial Statements, see Note 1 of the condensed notes to the Condensed Consolidated Financial Statements in this Form 10-Q and Note 1 of the notes to consolidated financial statements in our 2014 Form 10-K.

Application of Critical Accounting Policies

The preparation of financial statements in conformity with Generally Accepted Accounting Principles ("GAAP"), as promulgated in the United States, requires our management to make significant estimates and assumptions that affect the reported amounts of assets and liabilities, revenues and expenses and related disclosures in our Condensed Consolidated Financial Statements and accompanying notes. We believe the most complex and sensitive judgments, because of their significance to the Condensed Consolidated Financial Statements, result primarily from the need to make estimates and assumptions about the effects of matters that are inherently uncertain. The following accounting policies involve the use of "critical accounting estimates" because they are particularly dependent on estimates and assumptions made by management about matters that are uncertain at the time the accounting estimates are made. In addition, while we have used our best estimates based on facts and circumstances available to us at the time, different estimates reasonably could have possibly been used in the current period, and changes in the accounting estimates that we used are reasonably likely to occur from period to period both of which may have a material impact on our financial condition and results of operations. For additional information about these policies, see Note 1 of the Condensed Notes to the Condensed Consolidated Financial Statements in this Form 10-Q. Although we believe that our estimates, assumptions and judgments are reasonable, they are limited based upon information presently available. Actual results may differ significantly from these estimates under different assumptions, judgments or conditions. Revenue Recognition

The Company derives its revenues primarily from subscription and transaction fees pertaining to services delivered over our exchanges or from our ASP platforms, fees for business process outsourcing services, and fees for software development projects including associated fees for consulting, implementation, training, and project management provided to customers with installed systems.

In accordance with the Financial Accounting Standards Board ("FASB") and SEC accounting guidance on revenue recognition the Company considers revenue earned and realizable when: (a) persuasive evidence of the sales arrangement exists,

Table of Contents

provided that the arrangement fee is fixed or determinable, (b) delivery or performance has occurred, (c) customer acceptance has been received, if contractually required, and (d) collectability of the arrangement fee is probable. The Company uses signed contractual agreements as persuasive evidence of a sales arrangement. We apply the provisions of the relevant generally accepted accounting principles related to all transactions involving the license of software where the software deliverables are considered more than inconsequential to the other elements in the arrangement. For contracts that contain multiple deliverables, we analyze the revenue arrangements in accordance with the relevant technical accounting guidance, which provides criteria governing how to determine whether goods or services that are delivered separately in a bundled sales arrangement should be considered as separate units of accounting for the purpose of revenue recognition. Generally these types of arrangements include deliverables pertaining to software licenses, system set-up, and professional services associated with product customization or modification. Delivery of the various contractual elements typically occurs over periods of less than eighteen months. These arrangements generally do not have refund provisions or have very limited refund terms.

Software development arrangements involving significant customization, modification or production are accounted for in accordance with the appropriate technical accounting guidance issued by FASB using the percentage-of-completion method. The Company recognizes revenue using periodic reported actual hours worked as a percentage of total expected hours required to complete the project arrangement and applies the percentage to the total arrangement fee.

Allowance for Doubtful Accounts Receivable

Management specifically analyzes accounts receivable and historical bad debts, write-offs, customer concentrations, customer credit-worthiness, current economic trends and changes in our customer payment terms when evaluating the adequacy of the allowance for doubtful accounts.

Valuation of Goodwill and Other Indefinite-Lived Intangible Assets

Goodwill represents the cost in excess of the fair value of the net assets of acquired businesses. Indefinite-lived intangible assets represent the fair value of acquired contractual customer relationships for which future cash flows are expected to continue indefinitely. In accordance with the relevant FASB accounting guidance, goodwill and indefinite-lived intangible assets are not amortized but are tested for impairment at the reporting unit level on an annual basis or on an interim basis if an event occurs or circumstances change that would likely have reduced the fair value of a reporting unit below its carrying value. Potential impairment indicators include a significant change in the business climate, legal factors, operating performance indicators, competition, and the sale or disposition of a significant portion of the business. The impairment evaluation process first involves an assessment of certain qualitative factors to determine whether the existence of events or circumstances would indicate that it is more likely than not that the fair value of any of our reporting units was less than its carrying amount. If after assessing the totality of events or circumstances, we were to determine that it is not more likely than not that the fair value of a reporting unit is less than its carrying amount, then we would not perform the two-step quantitative impairment testing described further below.

The aforementioned two-step quantitative testing process involves comparing the reporting unit carrying values to their respective fair values. We determine the fair value of our reporting units by applying the discounted cash flow method using the present value of future estimated net cash flows. If the fair value of a reporting unit exceeds its carrying value, then no further testing is required. However, if a reporting unit's fair value were to be less than its carrying value, we would then determine the amount of the impairment charge, if any, which would be the amount that the carrying value of the reporting unit's goodwill exceeded its implied value. Projections of cash flows are based on our views of growth rates, operating costs, anticipated future economic conditions and the appropriate discount rates relative to risk and estimates of residual values. We believe that our estimates are consistent with assumptions that marketplace participants would use in their estimates of fair value. The use of different estimates or assumptions for our projected discounted cash flows (e.g., growth rates, future economic conditions, discount rates and estimates of terminal values) when determining the fair value of our reporting units could result in different values and may result in a goodwill impairment charge. We perform our annual goodwill impairment evaluation and testing as of September 30th of each year. This evaluation is done during the fourth quarter each year. During the year ended December 31, 2014 we had no impairment of our reporting unit goodwill balances.

Valuation of Contingent Liabilities related to Earn Out Obligations from Business Acquisitions
A significant component of the purchase price consideration for many of the Company's business acquisitions is a
potential subsequent cash earnout payment based on reaching certain specified future revenue targets. The Company
recognizes these potential obligations as contingent liabilities and are reported accordingly on its Condensed
Consolidated Balance Sheets. As discussed in more detail in Note 1 to the accompanying Condensed Consolidated
interim financial statements, these contingent

Table of Contents

consideration liabilities are recorded at fair value on the acquisition date and are remeasured quarterly based on the then assessed fair value and adjusted if necessary.

Income Taxes

Deferred income taxes are recorded to reflect the estimated future tax effects of differences between financial statement and tax basis of assets, liabilities, operating losses, and tax credit carry forwards using the tax rates expected to be in effect when the temporary differences reverse. Valuation allowances, if any, are recorded to reduce deferred tax assets to the amount management considers more likely than not to be realized. Such valuation allowances are recorded for the portion of the deferred tax assets that are not expected to be realized based on the levels of historical taxable income and projections for future taxable income over the periods in which the temporary differences will be deductible.

The Company also applies FASB accounting guidance on accounting for uncertainty in income taxes positions. This guidance clarifies the accounting for uncertainty in income taxes by prescribing the minimum recognition threshold a tax position is required to meet before being recognized in the financial statements.

Foreign Currency Matters

The functional currency for the Company's foreign subsidiaries in India and Singapore is the U.S. dollar because the intellectual property research and development activities provided by its Singapore subsidiary, and the product development and information technology enabled services activities for the insurance industry provided by its India subsidiary. both in support of Ebix's operating divisions across the world, are transacted in U.S. dollars. The functional currency of the Company's other foreign subsidiaries is the local currency of the country in which the subsidiary operates. The assets and liabilities of these foreign subsidiaries are translated into U.S. dollars at the rates of exchange at the balance sheet dates. Income and expense accounts are translated at the average exchange rates in effect during the period. Gains and losses resulting from translation adjustments are included as a component of other comprehensive income in the accompanying Condensed Consolidated Balance Sheets. Foreign exchange transaction gains and losses that are derived from transactions denominated in a currency other than the subsidiary's functional currency are included in the determination of net income.

Table of Contents

Item 3: QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK

The Company is exposed to foreign currency exchange rate risk related to our foreign-based operations where certain transactions are denominated in other than our entity's functional currency and are subject to market risk with respect to fluctuations in the relative value of those currencies. Most of the Company's transactions are denominated in U.S. dollars, however, the Company has significant and expanding operations in Australia, Brazil and Europe, and we conduct transactions in the local currencies of each of those locations. There can be no assurance that fluctuations in the value of foreign currencies will not have a material adverse effect on the Company's business, operating results, revenues or financial condition. During the six months ended June 30, 2015 and 2014 the net change in the cumulative foreign currency translation account, which is a component of accumulated other comprehensive loss within stockholders' equity, were unrealized gains (losses) of \$(4.0) million and \$2.6 million, respectively. The Company considered the historical trends in currency exchange rates and determined that it was reasonably possible that adverse changes in our respective foreign currency exchange rates of 20% could be experienced in the near term. Such an adverse change in currency exchange rates would have resulted in reduction to pre-tax income of approximately \$1.4 million and \$1.8 million for the six months ended June 30, 2015 and 2014, respectively.

The Company's exposure to interest rate risk relates to its interest expense on outstanding debt obligations and to its interest income on existing cash balances. As of June 30, 2015 the Company had \$151.1 million of outstanding debt obligations which consisted of a \$150.47 million balance on our commercial banking revolving line of credit, and a \$0.62 million in secured promissory note payable. The Company's revolving line of credit bears interest at the rate of LIBOR plus 1.50%, and stood at 1.94% at June 30, 2015. The Company is exposed to market risk in relation to this line of credit in regards to the potential increase in interest expense arising from adverse changes in interest rates. This interest rate risk is estimated as the potential decrease in earnings resulting from a hypothetical 30% increase in the LIBOR rate. Such an adverse change in the LIBOR rate would have resulted in a reduction to pre-tax income of approximately \$56 thousand and \$13 thousand for the six months ended June 30, 2015 and 2014, respectively. The Company's average cash balances during the six months ended June 30, 2015 were \$35.3 million and its existing cash balances as of June 30, 2015 were \$27.4 million. The Company is exposed to market risk in relation to these cash balances in regards to the potential loss of interest income arising from adverse changes in interest rates. This interest rate risk is estimated as the potential decrease in earnings resulting from a hypothetical 20% decrease in interest rates earned on deposited funds. Such an adverse change in these interest rates would have resulted in a reduction to pre-tax income of approximately \$21 thousand and \$53 thousand for the six months ended June 30, 2015 and 2014, respectively.

There were no other material changes to our market risk exposure during the six months ended June 30, 2015 and 2014. For additional information regarding our exposure to certain market risks, see "Quantitative and Qualitative Disclosures about Market Risk," in Part II, Item 7A of our 2014 Form 10-K.

Table of Contents

Item 4: CONTROLS AND PROCEDURES

Evaluation of Disclosure Controls and Procedures: The Company's management evaluated, with the participation of the Chief Executive Officer and Chief Financial Officer, the effectiveness of the Company's disclosure controls and procedures as of the end of the period covered by this report. Based on that evaluation, the Chief Executive Officer and Chief Financial Officer have concluded that the Company's disclosure controls and procedures were effective as of the end of the period covered by this report.

Internal Control over Financial Reporting: There were no changes in our internal control over financial reporting during the six months ended June 30, 2015, that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

Part II — OTHER INFORMATION

Item 1: LEGAL PROCEEDINGS

On December 3, 2012, the Company received a subpoena and letter from the SEC dated November 30, 2012, stating that the SEC is conducting a formal, non-public investigation styled In the Matter of Ebix, Inc. (A-3318) and seeking documents primarily related to the issues raised in the In re: Ebix, Inc. Securities Litigation. On April 16, 2013, the Company received a second subpoena from the SEC seeking additional documents. The Company has cooperated with the SEC to provide the requested documents.

On June 6, 2013, the Company was notified that the U.S. Attorney for the Northern District of Georgia had opened an investigation into allegations of intentional misconduct that had been brought to its attention from the pending shareholder class action lawsuit against the Company's directors and officers, the media and other sources. The Company is cooperating with the U.S. Attorney's office.

Following the announcement on May 1, 2013 of the Company's execution of a merger agreement with affiliates of Goldman Sachs & Co., twelve putative class action complaints challenging the proposed merger were filed in the Delaware Court of Chancery. These complaints name as Defendants some combination of the Company, its directors, Goldman Sachs & Co. and affiliated entities. On June 10, 2013, the twelve complaints were consolidated by the Delaware Court of Chancery, now captioned In re Ebix, Inc. Stockholder Litigation, CA No. 8526-VCN. On June 19, 2013, the Company announced that the merger agreement had been terminated pursuant to a Termination and Settlement Agreement, After Defendants moved to dismiss the consolidated proceeding, Lead Plaintiffs amended their operative complaint to drop their claims against Goldman Sachs & Co. and focus their allegations on an Acquisition Bonus Agreement ("ABA") between the Company and Robin Raina. On September 26, 2013, Defendants moved to dismiss the Amended Consolidated Complaint. On July 24, 2014, the Court issued its Memorandum Opinion. The only surviving counts are as follows: (i) Counts II and IV, but only to the extent the Plaintiffs seek non-monetary relief for alleged material misstatements related to the ABA base price in the 2010 Proxy Statement; (ii) Count II, but only to the extent it challenges the continued existence of the ABA as an alleged unreasonable anti-takeover device; and, (iii) Count V, but only to the extent that it relates to the compensation the Board received under the Company's 2010 Stock Incentive Plan. On September 15, 2014, the Court entered an Order implementing its Memorandum Opinion. On January 16, 2015, the Court entered an Order permitting Plaintiffs to file a Second Amended and Supplemented Complaint naming the individual directors and the Company as Defendants. As currently pled, the Second Amended and Supplemented Complaint asserts (i) a purported class and derivative claim for breach of fiduciary duty by the individual Defendants in improperly maintaining the ABA as an unreasonable anti-takeover device; (ii) a purported class claim against the individual Defendants for breach of the fiduciary duty of disclosure to the stockholders with respect to the Company's 2010 Proxy Statement and 2010 Stock Incentive Plan, (iii) a purported derivative claim against the individual Defendants for breach of fiduciary duty to the Company in causing incentive compensation to be awarded to themselves and others under the 2010 Stock Incentive Plan, (iv) a purported class and

derivative claim for breach of fiduciary duty by the individual Defendants in adopting the August 5, 2014 Credit Agreement, the November 26, 2014 Director Nomination Agreement with Barrington Capital Group, L.P. and certain bylaw amendments adopted December 19, 2014, (v) a purported class and derivative claim seeking invalidation of the December 19, 2014 bylaw amendments under Delaware law, and (vi) a purported class claim for breach of fiduciary duty by the individual Defendants for issuing a purportedly materially misleading and incomplete 2014 Proxy Statement. On February 10, 2015, Defendants filed a Motion to Dismiss the Second Amended and Supplemented Complaint, which is still pending. The Company denies any liability and intends to defend the action vigorously.

Table of Contents

The Company is involved in various other claims and legal actions arising in the ordinary course of business. In the opinion of management, the ultimate likely disposition of these matters will not have a material adverse effect on the Company's consolidated financial position, results of operations or liquidity.

Item 1A: RISK FACTORS

In addition to the other information set forth in this Quarterly Report on Form 10-Q, you should carefully consider the factors discussed in Part I, "Item 1A. Risk Factors" in our Annual Report on Form 10-K for the year ended December 31, 2014, which could materially affect the Company's business, financial condition or future results. There have not been any significant changes with respect to the risk factors described in Ebix's 2014 Annul Report on Form 10-K. The risks described in that 2014 Form 10-K and in this Quarterly Report on Form 10-Q are not the only risks that the Company faces. Additional risks and uncertainties not currently known to us or that we currently deem to be immaterial also may materially adversely affect our business, financial condition and/or operating results.

Table of Contents

Item 2: REPURCHASES OF EQUITY SECURITIES

The following table contains information with respect to purchases of our common stock made by or on behalf of Ebix during the six months ended June 30, 2015, as part of our publicly-announced share repurchase plan:

| Period | Total Number of Shares (Units) Purchased | Total Number of Shares Purchased as Part of Publicly-Announce Plans or Programs | Average Price Paid Per Share d(1) | Maximum Number (or Approximate Dollar Value) of Shares that May Yet Be Purchased Under the Plans or Programs (2) (3) |
|--|---|---|---|--|
| As of December 31, 2014 | 7,853,514 | 7,853,514 | \$ — | \$71,033,000 |
| January 1, 2015 to March 31, 2015 (4) | 994,869 | 994,869 | \$24.35 | \$46,809,000 |
| April 1, 2015 to April 30, 2015 | 125,000 | 125,000 | \$28.87 | \$43,200,000 |
| May 1, 2015 to May 31, 2015 June 1, 2015 to June 30, 2015 | 164,365 | 164,365 | \$27.57 | \$38,669,000 |
| | 60,000 | 60,000 | \$35.30 | \$36,551,000 |
| Total | 9,197,748 | 9,197,748 | | \$36,551,000 |

- (1) Average price paid per share for shares purchased as part of our publicly-announced plan.

 Effective lyne 30, 2011 the Company's Board of Directors unanimously approved an increase in the
 - Effective June 30, 2011 the Company's Board of Directors unanimously approved an increase in the size of the Company's authorized share repurchase plan from \$45.0 million to \$100.0 million. The Board directed that the repurchases be funded with available cash balances and cash generated by the Company's operating activities, and
- (2) be completed in the subsequent twelve months if possible. As of June 30, 2015 there are no remaining share repurchase authorizations for this plan. Under certain circumstances the aggregate amount of repurchases of the Company's equity shares may be limited by the terms and underlying financial covenants regarding the Company's commercial bank financing facility.
 - Effective June 21, 2013 the Company's Board of Directors unanimously approved an additional authorized share repurchase plan of \$100.0 million. The Board directed that the repurchases be funded with available cash balances and cash generated by the Company's operating activities, and be completed in the subsequent twenty four months
- if possible. Under certain circumstances the aggregate amount of repurchases of the Company's equity shares may be limited by the terms and underlying financial covenants regarding the Company's commercial bank financing facility.
- (4) As of March 31, 2015 there were 64,893 shares totaling \$1.94 million of share repurchases that were not settled until April 2015.

Item 3: DEFAULTS UPON SENIOR SECURITIES None.

Item 4: MINE SAFETY DISCLOSURES Not applicable.

Item 5: Other Information.

None.

Item 6: EXHIBITS

The exhibits filed herewith or incorporated by reference herein are listed in the Exhibit Index attached hereto.

Table of Contents

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

Ebix, Inc.

Date: August 10, 2015 By: /s/ Robin Raina

Robin Raina

Chief Executive Officer (Principal Executive Officer)

Date: August 10, 2015 By: /s/ Robert F. Kerris

Robert F. Kerris

Chief Financial Officer

(Principal Financial and Accounting Officer)

Table of Contents

EXHIBIT INDEX

Exhibits

| | Certificate of Incorporation, as amended, of Ebix, Inc. (filed as Exhibit 3.1 to the Company's Annual |
|-------|--|
| 3.1 | Report on Form 10-K for the fiscal year ended December 31, 2009 and incorporated herein by |
| | reference). |
| 3.2 | Bylaws of the Company (filed as Exhibit 3.2 to the Company's Annual Report on Form 10-K for the |
| 3.4 | fiscal year ended December 31, 2000 and incorporated herein by reference). |
| | Amended and Restated Bylaws of Ebix, Inc., effective immediately following the Company's Annual |
| 3.3 | Meeting of Stockholders, held on January 9, 2015 (incorporated by reference to Exhibit 3.1 to the |
| | Company's Current Report on Form 8-K dated December 24, 2014). |
| 21.1% | Certification of Chief Executive Officer Pursuant to Rule 13a-14(a) (Section 302 of the Sarbanes-Oxley |
| 31.1* | Act of 2002). |
| 21.2* | Certification of Chief Financial Officer Pursuant to Rule 13a-14(a) (Section 302 of the Sarbanes-Oxley |
| 31.2* | Act of 2002). |
| 32.1* | Certification of Chief Executive Officer Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002. |
| 32.2* | Certification of Chief Financial Officer Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002. |
| | XBRL (Extensible Business Reporting Language) - The following materials from Ebix, Inc.'s Quarterly |
| | Report on Form 10-Q for the quarter ended June 30, 2015, formatted in XBRL (eXtensible Business |
| 101** | Reporting Language): (i) the Consolidated Balance Sheets, (ii) the Consolidated Statements of Income, |
| | (iii) the Consolidated Statement of Stockholders' Equity and Comprehensive Income, (iv) the |
| | Consolidated Statements of Cash Flows, and (v) Notes to Consolidated Financial Statements which |
| | were tagged as blocks of text. |
| | |

^{*} Filed herewith

^{**}Exhibit 101 to this Quarterly Report on Form 10-Q is furnished and not filed for purposes of Sections 11 and 12 of the Securities Act of 1933 and Section 18 of the Securities Exchange Act of 1934.